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Historical Background
The first scientific approach to hay fever was documented and published 
in the "Medico-chirugical Transactions of London" in 1819 by John Bostock. It 
was entitled "Case of a Periodical Affection of the Eyes and Chest" and was an 
account of a single case, the patient himself, a London physician. In 1828 
Bostock termed the illness "hay asthma" and heat was thought to be the 
causative factor. Gordon in 1829 attributed the cause to "the aroma emitted by 
the flowers of grass". However, his view was not widely accepted by the 
medical profession until 1859 when further research by Professor Von Philip of 
Geissen reinforced this concept. In 1873, Charles Blackley, a Manchester 
homeopathic physician, and a sufferer himself, published the classic book, 
"Experimental Researches on the Cause and Nature of Catarrus aestivus (Hay 
Fever or Hay Asthma)", and identified pollen as the causative factor.
The term allergy, which is derived from the Greek 'alios' (altered) and 
'ergon' (reaction) was first used by the German pathologist Clemens Peter Von 
Pirquet in 1906. Since that time the immunological basis of allergies has been 
slowly unravelled. In  1913 Henry Dale made the fundamental discovery that 
the anaphylactic contraction of plain muscle was begun by antibodies fixed on 
cells, a concept that was totally foreign to the scientists of the time. Dale 
showed that the anaphylactic reaction released histamine, heparin and other 
substances. Frankland used controlled trial methods at St Mary's Hospital, 
London, to show the potential effectiveness of vaccines and also the role of 
released histamine and other inflammatory mediators.
xiv
Atopy or "out of place" was the term used by two Americans, Coca and 
Cooke, in 1923, referring to the differences between the allergic and non-allergic 
population.
Since Dale's day allergists have been aware of a possible "reaginic 
antibody" but it was not until 1966 that Ishizaka and colleagues confirmed 
Immunoglobulin E as the definitive reaginic antibody. Further work on the 
immunological aspects of allergy identified immunoglobulin G (IgG) as having 
a protective or ’blocking" role in the allergic reaction. Sub-class IgG4 was 
further investigated as the possible specific antibody sub-class involved in 
blocking the allergic reaction.
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ABSTRACT
In  this study the serum concentration of IgE and 
IgG4 (total and allergen specific taking Timothy grass 
pollen as the model allergen) have been investigated 
prospectively during and after pregnancy in healthy 
women and women suffering from allergic rhinitis.
The results show that the total serum IgG 
concentration remained unchanged in both groups during 
pregnancy. There was no significant difference in the 
serum concentration of IgG 4 between pregnant allergic 
women and non-pregnant allergic women. Levels of IgG4 
were approximately twice as high (p< 0.01) in non-allergic 
pregnant women compared to the non-allergic non­
pregnant control group. Total IgG4 concentrations were 
similar in allergic and non-allergic women during 
pregnancy; however, in the non-pregnant state allergic 
women had significantly (p = 0.017) higher levels of IgG4 
than non-allergic women.
The results show that both during pregnancy and 
in the non-pregnant state there was a highly significantly 
(p<0.001) greater serum concentration of total IgE in 
allergic than non-allergic subjects. Although the level of 
IgE was significantly (p=0.004) lower in pregnancy, the 
differences are relatively small and seem unlikely to be of 
great physiological significance. Allergic symptomatology 
did not correspond to IgE levels during pregnancy. In  
both the pregnant and non-pregnant women the serum 
concentration of antigen-specific IgE was highly 
significantly greater in the allergic than the non-allergic 
subjects. However, in allergic women, the concentration 
of antigen-specific IgE was very much lower during 
pregnancy, at about 6% of the non-pregnant level 
(p<0.001). The concentration of antigen-specific IgG4 was 
also reduced in pregnancy in allergy sufferers, being 
about half of the level found in the non-pregnant 
individuals (p<0.001).
There appeared to be an increase in spontaneous first 
trimester abortion in women who suffered symptoms of 
allergy. From the case histories of all 418 pregnancies at 
the Langold Health Centre ante-natal clinic attending 
between September 1976 and December 1990,192 were to 
allergy sufferers and 226 were to normal women. The 
abortion rate was 16.7% in the allergic group and 5.3% in 
the normal pregnant women (p < 0.001).
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CHAPTER ONE
THE IMMUNOBIOLOGY OF ALLERGIC RESPONSE
1
1.1 Atopy and the Allergic Reaction.
Atopic individuals mount an immune response to an environmental 
antigen with the production of IgE. When this specific IgE interacts w ith the 
eliciting allergen, cross-linking of the F e receptors on mast cells occurs, resulting 
in their degranulation and release of preformed mediators of the allergic 
reaction such as histamine and heparin. In addition, newly-formed mediators, 
such as certain prostaglandins and leukotrienes, are synthesised. Mast cell 
triggering also requires lymphokines, particularly IL4, produced by activated 
lymphocytes.
T-cell responses to mitogen stimulation are reduced in some atopies, and 
both histamine and some prostaglandins can suppress in vitro mitogen- 
stimulated lymphocyte transformation. Both defects of T-cell activity and 
abnormal responses to mediators of allergy have been implicated as the cause 
of allergic reactions. Chowdury and Chandra (1989) recently reviewed studies 
on immunoregulatory T-cell abnormalities in patients with atopic disease. Of 
18 studies, 12 reported a reduction of total T-cell numbers and also showed that 
suppressor T-cells are reduced in atopic patients. In  infants, the reduction of 
suppressor T-cell numbers precedes the development of allergies. Thus, a 
deficiency of suppressor T-cells would result in an increase in IgE production 
and thus enhance the risk of atopy. In addition to control at the cellular level, 
the function of IgG4 as a blocking antibody in the allergic reaction in general 
and among atopic individuals in particular is now well established.
1.2 Types of Hypersensitivity Reactions.
In 1963 Gell and Coombs classified hypersensitivity reactions into four 
types - Types I, II, I I I  and IV. A fifth type, 'stimulatory', has since been added
2
in which non complement-fixing antibodies directed against certain cell surface 
components may actually stimulate rather than destroy the cell. Theoretically 
stimulation could also occur through the development of antibodies to naturally 
occurring mitotic inhibitors in the circulation (Roitt, 1984). Table 1 (page 4) 
shows the important features of reaction Types 1-1V.
Type I  reactions are discussed in full detail in Section 1.3.
1.3 Development of Type 1 Hypersensitivity Reactions. (IgE Mediated 
Hypersensitivity).
Such allergic reactions proceed in three phases - the sensitization phase, the 
activation or challenge phase and the effecter phase.
Phase 1 - The Sensitization Phase.
The reaction begins when a genetically pre-disposed individual encounters a 
protein antigen of the appropriate molecular configuration to serve as an 
allergen. Such allergens can be airborne or ingested or arrive in the blood 
stream directly, e.g. by injection. At this point, interaction w ith cells of the 
immune system must occur for sensitization to be completed. IgE antibody 
synthesis is a T cell-dependent immune process. Antigen-presenting cells, often 
macrophages, present processed antigen in association with M H C  class II  
molecules on their surface to helper T-cells (TH). IL-1, secreted by the
macrophages at the time of antigen presentation, stimulates precursor helper TH  
cells to differentiate and mature. Mature TH  cells secrete a second soluble 
factor, interleukin 2 (IL-2), which promotes clonal expansion of T H  cells and 
stimulates the differentiation of B cells into antibody-secreting plasma cells. IgE 
antibody synthesis is a T cell-dependent immune process. Thus, cooperation
3
Ty
pe
s 
of 
Hy
pe
rse
ns
itiv
ity
 R
ea
cti
on
.
30•Hi PP T3 CO cd0 0 P Pa >i4-> P 3 3Sh p  <d 0 0 •oJ3 -H -H P  35> T3 4-1 73> TJH  0 (d rH CO 0H 0 P  g cd S* 73>vH 1 P  p cd 30| cd CO rH 0 0 -d 0a H  C H CO > P0 0  0 3 0 P X
N Q CO o O CO 0 W
P>1 0 073 P >O X 0 10JQ P •H P•H 3 0 0 3P 0 0 03 4-1 P 73 33cd CO cd 3H 1 3 P 4H £H 3 •H 3 rH 0H 0 0 3 «*4-ttr» p  35 g 00 •H 0 •H P Pa P 0 X X 3 X> 3 3 -H cd 0 0EH < O 0 S 3  3
0p I
0 P 3•H 0 0 CNX P  330 4-1 3 0H p 3 rH 0 PH 0 cd •H 3p P  P P  00 0 0 0 cd .3Q p 0 > P> >1 3 0 3 ooEH u O 0 Q
O 3•H •H 3 0P 35 0 •H P0  0 p  0 3P  cd •H P 0 0Cd rH £ 3 0 33H •H >i 3 >73 35 P  -H rH 00 0 a 0 g 0 0a g cd 0 0 P> e 3 3 O 0 3!EH H Cd O *H «  P
cd
e0 0•H N0 0•• 0 00 rH0 3 prH O cd 0 cda p g cd gg 0 3 P  .3cd 33 P 3 PX 3 0 0 0W EH <! O <
co•H
•H r—Icd
CO * H  U  * H  c d
Q ) C O 'H  M  CO W•H tr»P p cd
OJ p .H 73 P -P
X 0  «H 3  Cd 0H C/3 <Jj H fa rfj
QJ
£
p  0•H 0  3  ^> -H  P <•rlTJ OP  jQ 3  3•H O £  O §•• 0  *H 0 -H CO u,CO 3  P  3  0  3  P-h0 0 >i 3 0 rH 0  rH 0  4H *H 04 P 0 X 3  W+> g 0  g P  3  U cd a 0 cd cd X >i 0 m-i p 0  W S3 S3 o  Eh P
0tr*3•H
P\ 0
•  • P0 0 a0 > 0iH 0 3a b  &
£cd 0X cd 0W S3 S3
4
takes place between B and T lymphocytes and antigen presenting cells in the 
induction of an antibody response to most protein antigens.
Once this process is complete, each plasma cell elaborates antibody 
of a single antigen-binding specificity, although switching between
immunoglobulin classes can occur. The IgE antibody molecules produced are 
specific and interact through their Fab region only with the antigen that 
stimulated their synthesis (Ishizaka et al., 1975).
Synthesised IgG antibodies either sensitise mast cells locally at the site 
of IgE production or are transported in the blood and sensitise mast cells and 
basophils distal to the site of production. Sensitisation occurs when IgE binds 
to high affinity Fc receptors previously on mast cells, but also on blood 
basophils. Blood-borne IgE antibodies are synthesized in respiratory or 
gastrointestinal lymphoid tissue and consequentially bind to mast cells in the 
skin and other organs. The binding of IgE with mast cells is reversible.
Phase 2 - The Activation or Challenge Phase
Following a second exposure to and interaction of sensitized host 
mast cells with an allergen, the antigen bridges two adjacent cell bound IgE 
molecules of identical specificity and brings the two receptor molecules into 
proximity (Fadal et al.. 1981). This cross-linking of cell-bound IgE results in 
complex, enzyme-associated biochemical events which culminate in a decline 
of intracellular cAMP concentration and the facilitation of degranulation of mast 
cells with the release into the micro-environment of granules containing
i
histamine and other preformed mediators into the micro-environment.
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Phase 3 - The Effector Phase.
The principal preformed mediators released during the degranulation of 
mast cells are histamine and heparin. Acting via H I receptors histamine causes 
constriction of smooth muscle resulting in, for example, bronchoconstriction and 
increased capillary permeability. Acting via H 2 receptors histamine stimulates 
mucus gland secretion. Heparin has a blood anti-coagulant effect. The 
eosinophil chemotactic factor ECF-A, also a preformed mediator, results in 
eosinophil accumulation. The histamine enzyme of eosinophils may act in a 
regulating capacity. Other observed phenomena, such as platelet aggregation, 
neutrophil accumulation and other post-inflammatory activities are mediated by 
newly synthesised products of mast cells.
1.4 Immunoglobulins and Allergens
Of the five classes of immunoglobulins, two, IgE and IgG, are of proven 
importance in allergic reactions.
1.4.1 Immunoglobulin E - The Human Reaginic Antibody.
The presence of reaginic antibodies in the sera of atopic patients was first 
demonstrated by Prausnitz on his patient Kustner. In 1966, Ishizaka et al. 
discovered the presence of IgE and established its structure, properties and 
defined its role in allergic reactions. These immunoglobulins are present in 
small amounts in the peripheral circulation compared to IgG and IgM . 
Allergen-specific IgE occurs at even lower concentration and is present at 
picogram/ml levels. For comparison, IgE normally occurs at 1 /10,000th - 
1 /500,000th of the concentration of IgG. 99.99 per cent of IgE in blood remains 
free and is not bound to blood basophils (Fadal 1985).
6
IgE is responsible for Type I  immediate hypersensitivity reactions and is 
implicated in anaphylaxis, allergic rhinitis, allergic asthma, immediate food 
allergy, atopic dermatitis, hypmenoptera sensitivities and certain drug and 
chemical reactions. In  previously sensitised patients, a small allergic stimulus 
may evoke immediate hypersensitivity reactions following the interaction of 
antigen and specific IgE antibody on the surface of the mast cell. This results 
in anaphylactic degranulation with granule content extrusion from either the 
mast cell or the basophil. Thus IgE acts as an efficient liberator of histamine 
and other pharmacological mediators. This release is dependent on the 
activation of adenyl cyclase within the plasma membrane of 
mediator-containing cells and does not involve complement activation or cell 
damage.
1.4.2 The Structure and Physiological Activities of IgE
IgE protein has kappa and lambda light chains and possesses characteristic 
antigenic determinants not shared by other immunoglobulins of known classes 
and sub-classes. The antigenic structure of IgE as well as association of 
antibody activity with the protein indicate that IgE represents a distinct 
immunoglobulin class. Physicochemically, IgE is a glycoprotein w ith a 
sedimentation coefficient of 8S and molecular weight of around 200,000. The 
protein is composed of two heavy and two light polypeptide chains. The 
specific antigenic determinants are present in the Fc portion of the heavy chains. 
The carboxyl terminal of the Fc portion of IgE is essential for sensitization, and 
IgE molecules combine with receptors on target cells through the Fc portion of 
the immunoglobulin molecules.
7
Some important biological activities of IgE are shown in Table 2 (page 9).
1.4.3 Regulation of IgE Production and Synthesis
The regulation of IgE production is not clear. B cells bearing IgE are 
detectable at 11 weeks in the fetus, but production of IgE in utero is negligible 
and IgE is undetectable in umbilical cord blood in most infants. Maternal IgE 
antibody does not efficiently cross the placenta. Observations confirm that 
children with increased IgE levels in the first year of life have a significantly 
greater chance of developing allergy later in childhood and also there is a 
familial tendency in allergic disease.
IgE is produced by T cell-regulated B cells, which transform into antibody 
secreting plasma cells. These are primarily in lymphoid tissue of the respiratory 
and gastrointestinal tract. Tonsils and adenoid tissue contain the highest 
concentrations of such cells. After local production, IgE is transported in the 
blood or diffuses into tissues and mucosal secretions. Once in the blood, only 
0.01% IgE fixes to basophils and the rest circulates to other tissues for mast cell 
binding. The most important biological property of IgE antibody is the ability 
to sensitise homologous tissue for allergic reactions by reversibly binding with 
high affinity to specific membrane receptors on basophils and mast cells. Mast 
cells are of primary importance in mediator release and the cells thus precipitate 
allergic inflammation. Mast cells and basophils contain upwards of 80,000 IgE 
receptor sites per cell.
In  normal human subjects, peripheral blood B-lymphocytes do not 
synthesise IgE. However, in atopic individuals peripheral blood lymphocytes
8
TABLE 2
IMPORTANT BIOLOGICAL PROPERTIES OF IgE
T i s s u e  h a l f - l i f e  
S e r u m  h a l f - l i f e  
S e r u m  l e v e l s
D i s t r i b u t i o n  i n  s e c r e t i o n s  
P l a c e n t a l  t r a n s f e r  
P K  r e a c t i v i t y  
C o m p l e m e n t  f i x a t i o n  
R e c e p t o r s  f o r  F c  o n  
B a s o p h i l s  
M a s t  c e l l s  
M o l e c u l a r  w e i g h t  o f  h e a v y  c h a i n s  
C  a r b o h y d r a t e
I g E  m o l e c u l a r  w e i g h t  ( D a l t o n s )
21 days 
2.5 days 
< 0.5 mg/L 
+
+ (10 pg of antibody required)
+ (alternate pathway only)
+
+
72 x 103 Da 
12 per cent 
19 x 104
 1
( F a d a l ,  1985)
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spontaneously synthesize IgE in vitro and in such individuals the concentration 
of IgE increases following exposure to allergen during the pollen season.
The IgE-specific regulatory T cells with helper or suppressor activity have 
been demonstrated to bear Fc receptors for IgE. These receptors are shed into 
the micro-environment and can be detected as IgE binding factors because of 
their ability to bind IgE. These IgE binding factors stimulate IgE-producing 
memory B cells and regulate their differentiation into plasma cells. Plasma cells 
secrete more IgE antibody or provide suppressor signals to shut off IgE 
antibody production. The balance between these two signals w ill determine the 
magnitude of the IgE antibody response. Helper T-cells (CD4+ cells) and 
suppressor T cells (CD8+ cells) are responsible for modulating such activities 
(Geha et al., 1984).
1.5.1 Immunoglobulin G (IgGl and its Subclasses
IgG is the major circulating immunoglobulin. There are four IgG 
subclasses, differing both immunochemically and functionally (Heiner, 1984). 
Different subclasses appear to relate to different disease stages (Oxelius, 1984). 
IgG subclass 4 has a role in allergic disease.
1.5.2 IgG Subclass 4 - its Distribution and Significance in Human Diseases 
In  a community survey of IgG4 antibody levels in the U.K. (Merrett et al.,
1983) precise and specific radioimmunoassays were developed to quantify total 
IgG4 and IgG4 antibodies. It was demonstrated that men have significantly 
higher total serum IgG4 levels than women (mean value in males 0.581 m g/m l; 
in females 0.302 m g/m l) comprising 0.7% of total serum IgG, the range 15 mg - 
185 m g/m l, (Shakib, 1975)) and quantitatively makes it the least abundant of
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the four IgG sub-classes. Van Der Giessen (1975) reported that serum IgG4 
levels increase slowly from birth until reaching adult levels around 12 years of 
age. Circulating levels of IgG4 antibodies with specificities directed against 
food components, especially egg and milk, are normally higher than those 
against common inhalant allergens, such as grass pollen, house dust mite and 
cat epithelium.
The role of IgG4 as part of general common mucosal immunological 
reactions and as protective in allergy in particular is gaining increasing support 
from the work of many investigators (Heiner 1980, Perelmutter 1983, Aalberase
1983). It has been suggested that sub-types IgG4a and IgG4b are responsible for 
the anaphylactic and blocking activities of IgG4 subclass immunoglobulins 
respectively (Gwenn, 1978; Perelmutter, 1983). In recent reviews (Halpem, 
1983; Perelmutter, 1983) it has been postulated that the possible mechanisms 
for these activities are that IgG4 sensitises target cells for mediator release on 
antigenic challenge and at the same time acts as a protective antibody in allergic 
disease.
The role of IgG4 in allergy is still controversial and conflicting reports of 
IgG4 involvement in allergy are common. In  studies on histamine release from  
basophils by anti-IgG4, three positive and one negative report have appeared. 
Similarly in the case of membrane receptors for IgG4 on mast cells three 
positive and three negative reports have been published (Nakagawa, 1983). In  
addition, the sera from atopic patients have been shown to be capable of 
positively sensitising leucocytes from non-atopics for histamine release with  
anti-IgG4 (Vijoy, 1978).
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In  order to assess the passive protection by IgG antibodies, Lessof et al.. 
(1978) isolated the gammaglobulin fraction of plasma from bee keepers and 
injected it into five subjects allergic to bee venom. The bee keepers globulin 
conferred passive protection. However, this protection was transient. 
Nevertheless a rapid IgG antibody response was noticed and confirmed that IgG 
antibody may indeed have a 'blocking' role. Kemney (1983) studied the role of 
different sub-classes of IgG in an attempt to categorise the role of the antibody 
response. His study showed, as Aalberse (1983) had initially demonstrated, that 
an initial IgG l response to bee venom switches to a more sustained IgG4 
response.
Heiner (1980) was the first investigator who produced evidence that IgG4 
might be a protective or blocking antibody as well as a skin sensitising antibody 
when he examined the IgG4 serum levels in novice and experienced bee 
keepers. Since then a number of papers have been published on IgG4 and bee 
keepers. W ith every bee sting roughly 50 ug of venom is deposited under the 
skin. In a sensitised subject the reaction to a bee sting may range from a mild 
or a severe local reaction, to a generalised response entailing urticaria, 
angiodema, asthma or life threatening anaphylaxis. In a recent study published 
in Sweden, Lojmnitzer et al., (1988) suggested that there may be two 
immunological types of bee allergic patients. The first type behave as expected 
by producing high levels of IgE, IgG and lymphocyte proliferation in response 
to the bee venom. The second type, however, show very low levels of these 
immunological responses. There was no clinical differentiation in both groups 
as they had equally severe allergic reactions and positive skin tests to bee 
venom.
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Jarisch (1986) has shown that non-allergic volunteers produce either no 
response to bee venom injections or a transient IgE antibody response, which 
disappears within six months. In contrast, after being stung by live bees, atopic 
people with a tendency to allergy produce a much more vigorous and 
prolonged sensitising response, which can also be seen in some non-allergic 
subjects. Inevitably this may be seen as supporting evidence for the view that 
allergy is a failure of the mechanism that normally suppresses IgE after the first 
sensitisation has passed but might still be goaded into action by repeated 
injections of antigen (Lessof, 1986).
1.5.3 Structure, Antigenic Characteristics and Distribution of IgG 
Sub-Class 4
The four human IgG sub-classes differ in the number and/or distribution 
of interchain disulphide bonds, which undoubtedly influence their varying 
susceptibility to proteolysis. Soloman and co-workers (1978) found that IgG2 
and IgG4 were more resistant to digestion by neutrophil elastase than were 
IgG l and IgG3 and suggested that this stability contributed to effective 
phagocytosis and bacterial killing in tissues in which there is active 
inflammation.
It has been suggested that the carbohydrate prosthetic group of the four 
human IgG sub-classes may have inherent, distinctive structural differences 
which could be of biological significance (Stanworth, 1983). For example, in 
addition to the differences in amino acid sequence within the heavy chains of 
the four human IgG sub-classes, other genetic differences are seen. These 
allotypic differences in IgG4 are divided into two types, IgG4a and IgG4b. 
These antigenic determinants, located in the heavy chain, are related to
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determinants shared with other IgG sub-classes. It has been shown that the 
distinctive antigen of the common 4a type is shared with all IgG l and IgG2 
sub-classes (Kunkel, 1970). In addition, IgG4 is distinguished from the other 
three IgG sub-classes at the physicochemical level by its faster electrophoretic 
mobility.
Biologically, IgG4 cannot activate the classical complement pathway, 
differentiating it from the other IgG sub-classes. Studies have shown that the 
Clq binding site is present on IgG4 protein but this is shielded by the molecules 
Fab region (Stanworth, 1983). It has also been reported that IgG4 is functionally 
univalent, this being discovered when testing IgG4 antibody in a system with 
antigen coated polystyrene tubes and radio-labelled antigen (Aalberse, 1983). 
This univalent characteristic is shared by IgE molecules. On the other hand IgG 
sub-classes 1, 2 and 3 are bivalent and can readily form insoluble immune 
complexes.
1.6.1 The Primary Effectors of Immediate Hypersensitivity: The Mast Cell
The mast cell was first described by Ehrlich in 1877 and is involved in a 
wide variety of inflammatory processes. Mast cell degranulation was observed 
in the 1930s following intraperitoneal injection of various irritants in rats which 
induced generalized urticarial reactions. The reaction appeared to be 
anaphylactic, a phenomenon first described by Portier and Richet in 1902. In  
man, mast cells are thought to be derived either from lymphoid precursors, 
thymic epithelial cells, histiocytes, undifferentiated mesenchymal cells or 
reticular cells (Mitchell, 1983). In the mouse, mast cells appear to be of bone 
marrow origin. Their precursor cells leave the marrow and enter the tissues 
where they slowly differentiate into mast cells. However, as
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lymphocyte-derived factors can promote proliferation in tissue culture, at least 
some mast cells appear to be thymic dependent (Ginsburgh et al.. 1978). Mast 
cells are ovoid-shaped, 10-30 um in length and contain many dense cytoplasmic 
granules. These granules stains metachromatically using a variety of dyes and 
average 0.2 to 0.4 um in diameter. In  human mast cells, the granules can 
appear to have a scroll-like structure.
The suggested biological functions of mast cells include parasite rejection, 
repair of connective tissue, regulation of microvasculature, regulation of gastric 
acid secretion and detoxification of surrounding tissues. These cells are the 
primary effectors of immediate hypersensitivity reactions. Among all the 
populations of immunologically active cells, they are unique in that they possess 
a recognition system already in situ. Sensitized IgE-bearing mast cells can 
recognise foreign configurations (non-self) without recruitment of other cells 
from the immune system. These cells are widely distributed but are noticeably 
present in connective tissue, particularly surrounding blood vessels, nerves and 
glandular ducts. The cells are prominent in the skin, lymphoid tissue, lung, 
bladder, uterus, synovium, mesentery and submucosal and subserosal layers of 
the digestive tract.
1.6.2 Mast Cell Heterogeneity in the Human
Two types of human mast cells have been predicted, based upon the 
characterization in rodents of mucosal and connective tissue types of mast cells. 
Each type of rodent mast cell contains histamine and undergoes IgE-mediated 
activation and IgE mediated secretion, but they differ in their staining and 
fixation characteristics, growth conditions, susceptibility to non IgE-dependent 
secretagogues and in the specific proteases, and proteoglycans present in their
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secretory granules. Their designation as mucosal and connective tissue mast 
cells has been based on the predominance of the former type in the small bowel 
mucosa and the later type in skin. Both sub-sets, however, are often present 
together in the same tissue. In humans, heterogeneity based on fixation or 
staining characteristics has not been as clear as in rodents. Nevertheless, two 
mast cell types are now recognized by their different protease compositions. 
Those containing tryptase alone have been termed T mast cells and those 
containing tryptase together with chymase have been termed TC mast cells.
Further functional and compositional properties of each subset need to be 
determined. T mast cells are present at about 21,000/m m 3 in small bowel 
sub-mucosa; TC mast cells at 8,500/m m 2 in small bowel sub-mucosa and 
3,000/m m 3 in skin.
The distribution of mast cell types in human lung is as follows: 
the percentage of T mast cells in alveolar wall and in bronchial/bronchiolar 
subepithelium is greater than 90%, in bronchial/bronchiolar subepithelium is 
70% and in nasal mucosa is about 50%. In human lung, concentrations of mast 
cells are highest in alveolar tissue (26,500/m m 3) and in bronchial/bronchiolar 
subepithelium (18,000/mm3).
1.7.1 Generation and Release of Mediators of Allergy in Man.
Allergic reactions are expressions of amplification mechanisms that are 
selectively triggered by recognition of an allergen. These intrinsic reactions are 
pre-determined and have characteristics which are determined by the dose of 
the allergen. The clinical manifestations of allergic reactions are mostly 
physiological responses to the release or generation of predominantly low 
molecular weight mediators with considerable biological potency. When
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allergens interact with circulating immunoglobulin, with cell bound 
immunoglobulin or with antigen recognition sites on mast cells, this results in 
the liberation of both preformed and newly synthesized mediators, which 
together orchestrate the development of the inflammatory response. Newly 
generated mediators are synthesized de-novo and secreted after IgE dependent 
activation by mechanisms independent of secretory granule exocytosis. They 
are not stored in appreciable quantities in the mast cell. They include 
metabolites of arachidonic acid Leukotriene C4 [LTCJ and Prostaglandin D 2 
[PGDJ the phospholipid derivative PAF and the nucleoside adenosine.
1.7.2 Preformed Mediators
Preformed mediators of mast cells include histamine, heparin and 
chemotactic factors.
Histamine is the only biogenic amine detected in human mast cells. 
Histamine is synthesized in mast cells by the action of histidine decarboxylase 
on histidine and is stored in cytoplasmic secretory granules. These granules are 
acidic and histamine is probably bound to negatively charged carboxyl or 
sulphate groups in the proteoglycan-protein (heparin) matrix of the granule. 
After release into the neutral pH extra-cellular environment, histamine becomes 
less positively charged, dissociates from the complex and is freely soluble. 
Histamine expresses its biological activity by binding to H j and H 2 receptors on 
the membranes of target cells.
In  skin, histamine elicits a response consisting of an initial local erythema 
due to arteriolar vasodilation mediated via an axon reflex, and later a central 
edematous wheal due to enhanced capillary permeability.
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Enhancement of local vasopermeability by released histamine facilitates the 
tissue deposition of plasma components, and permits the interaction in tissues 
of plasma components with released mast cell neutral proteases. Contraction 
of bronchial and gastrointestinal smooth muscle occurs via H x receptors, 
whereas gastric acid secretion by parietal cells is mediated via H 2 receptors. 
Histamine is an airway constrictor. It also increases vascular permeability to 
plasma components at the level of the postcapillary venule by increasing the 
pore size between adjacent endothelial cells. Intravenous infusion of histamine 
causes increased heart rate and pulse pressure along with diastolic hypotension, 
flushing, and headache.
In vitro histamine expresses other activities, which are not yet fully  
evaluated in vivo. Thus, the activation of histamine H 2 receptors (Melmon &  
Rocklin, 1981) results in the down-regulation of T-lymphocyte-mediated 
cytotoxicity, the release of lymphokines and the proliferation of lymphocytes. 
Stimulation and the secretion of granule mediators by neutrophils, basophils 
and mast cells along with augmentation of T lymphocyte suppression activity 
also occurs.
Histamine is also chemokinetic for eosinophils and neutrophils (Lewis,
1984). Although histamine is not chemotactic for the migration of these cells, 
it does increase their random non-directional movement. Chemokinetic 
influences on cells makes them more able to respond to chemotactic factors. 
Thus, histamine is an effector of neutrophil and eosinophil migration by 
rendering the migratory cells more active, while not directing their movement. 
Histamine thereby increases the potency of eosinophil chemotactic factor of 
anaphylaxis (ECF-A).
The biological half-life of released histamine is short, greater than 90% 
being metabolized after one pass through the circulation. The main catabolic 
pathway involves the action of histamine methyl transferase and diamine 
oxidase.
In clinical situations, such as in patients suffering from anaphylaxis 
provoked by exercise or antigen, mastocytosis, angiodema and cold urticaria, 
serum histamine levels are found to be elevated (Heavey et al.. 1986). After 
challenge by specific antigens in patients with atopy, histamine has been 
demonstrated in nasal lavage fluid and skin-blister fluid.
1.7.3 Chemotactic Factors
Mast cell degranulation results in the influx of secondary cells, particularly 
eosinophils, neutrophils, and lymphocytes. Mast cells are thought to release 
factors capable of recruiting these secondary cells to the sites of immediate 
hypersensitivity reactions. Mediators chemotactic for eosinophils are collectively 
called "eosinophil chemotactic factors of anaphylaxis." These include two acidic 
tetrapeptides, Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu, which account for part of 
the low molecular-weight chemotactic activity and are active at concentrations 
as low as lO^M. In addition to causing chemotaxis, exposure to these 
tetrapeptides desensitises eosinophils to any further chemotactic effects and 
increases the expression of receptors for complement components C4b and C3b 
on these cells. Another protein presumably of mast cell origin, of molecular 
weight 750,000 and which attracts neutrophils (Neutrophil Chemotactic Factor, 
NCF), has been found to be released into the venous effluent during 
experimentally-induced attacks of physical allergy in patients w ith cold or
cholinergic urticaria. This protein has been implicated in bronchospasm 
induced by specific allergens. The release of these chemotactic factors into the 
circulation is antigen and dose dependent. This release is inhibited by 
pre-treatment with sodium chromoglycate.
1.7.4 Proteases
Mast cells are rich in intragranular proteases which are released during 
immunological activation. These are strongly positively charged at 
physiological pH  (isoelectric point pH 9) and are active at neutral pH. In some 
species, such proteases constitute up to 50 per cent of the total mast cell protein. 
The functional relevance of these enzymes in the mast cell response is indicated 
by the diminution of skin lesions in experimental hypersensitivity after protease 
inhibitors are administered. The two major neutral proteases of human mast 
cells are tryptase and chymase. Tryptase is the principal protease of the 
secretory granules of human mast cells and can also be detected, by 
immunoassay, in experimental skin chamber fluid after cutaneous allergen 
challenge. No other cell type - including those found in normal lung, small 
intestine and skin, or eosinophils, basophils, neutrophils, monocytes or 
lymphocytes has been found to contain appreciable amounts of tryptase. 
Tryptase release is therefore a useful marker of mast cell activation (Schwartz 
et al.. 1981).
Tryptase is stored and secreted as a tetramer composed of two 35 
kilodalton KDa and two 37 KDa sub-units (Schwartz, et al.. 1981). In  recent 
work by Schwartz and Bradford (1986) it was found to be a tetrameric serine 
endoprotease of 134,000 M r (monomer) with sub-units of 33,000 M r and 34,000 
M r each with active sites. The sub-units also share antigenic sites. It is not
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known whether the M r difference between the two sub-units reflect distinct 
primary amino acid sequence differences or differences in post translational 
processing of identical gene products. Like pancreatic trypsin, tryptase is an 
endopeptidase. Tryptase stored in secretory granules is fully active and is not 
inhibited by any protease inhibitors found in plasma. The enzyme is stabilized 
in its active tetrameric form by association with the proteoglycan heparin. 
When free in solution, tryptase sub-units rapidly dissociate into inactive 
monomers.
The possible biological functions of tryptase and chymase include digestion 
of blood-vessel basement membrane with resultant increased vascular 
permeability, degradation of connective-tissue components such as the peptide 
core of proteoglycans allowing the influx of secondary inflammatory cells and 
the degradation of debris and activation of growth factors to promote wound 
healing. Plasma proteins, including angiotensin 1 and complement C3, have 
been shown to be substrates for mast-cell proteases in vitro. Tryptase however 
has no effect on complement component C5. Tryptase rapidly inactivates 
fibrinogen as a coagulable substrate for thrombin.
Chymase is the second protease found in secretory granules of human mast 
cells, particularly those from the skin and intestinal submucosa. It exhibits a 
cleavage pattern similar to that of pancreatic chymotrypsin. Unlike tiyptase, 
chymase is not present in all mast cells. Chymase is a serine endoprotease of 
30,000 M r (monomer). Like tryptase, chymase is stored in mast cell secretory 
granules as a fully active enzyme and is presumably bound to the negatively 
charged granular proteoglycan. Unlike tryptase, chymase is inhibited by plasma 
proteinase inhibitors.
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Additional proteases associated with human mast cells include those with 
Hageman factor-deriving, Hageman factor-activating, Kalikrein, pre Kalikrein 
activating, elastase, and cathepsin G1 activities.
1.7.5 Proteoglycans
Proteoglycans consists of glycosaminoglycan side chains (repeating 
disaccharide units of uronic acid and hexosamine that are variably sulphated) 
covalently linked to a protein core via a trisaccharide-protein linkage sequence 
of galactose-xylose. These are present in the secretory granules of mast cells. 
Two classes of proteoglycan, heparin and chondroitin sulphate have been 
localized in distinct rodent mast cell subsets (Katz et al.. 1985). A similar 
distribution has been suggested in humans where heparin has been found 
associated with lung and skin mast cells and chondroitin sulphate has been 
associated with intestinal mast cells.
The molecular weight of the heparin proteoglycan in human mast cells is 
60 to 150 KDa. A high degree of sulphation - 300 to 1000 sulphate residues per 
molecule - makes heparin the most negatively charged molecule in the body 
and probably accounts for the characteristic metachromatic staining of mast cells 
by certain basic aniline dyes, such as toluidine blue. Heparin has a structure
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with an average of 2.5 sulphate groups per disaccharide The protein core in rat 
heparin consists predominantly of the amino acids glycine and serine (43%).
Chondroitin monosulphates are sulphated either in position 4 (chondroitin 
4-sulphate, chondroitin sulphate-A) or position 6 (chondroitin 6-sulphate, 
chondroitin sulphate-C) of galactosamine residues. Disulphated disaccharides 
have been found with sulphate groups in positions 4 and 6 of galactosamine
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(chondroitin 4,6-disulphate, chondroitin sulphate E) and in positions 4 of 
galactosamine and 2 of iduronic acid (disulphated chondroitin sulphate B, 
chondroitin sulphate di-B). The core protein structure of chondroitin sulphate 
E proteoglycan (averaging 1.5 sulphate groups per disaccharide) from mouse 
bone marrow derived mast cells consists predominantly of glycine (43%) serine 
(17%) and glutamic acid (10%). The chondroitin sulphate di-B (1-2 sulphate 
groups per disaccharide) proteoglycan from rat bone marrow derived mast cells 
is predominantly glycine (35%) serine (23%) and alanine (10%). A ll these 
protein cores are markedly resistant to digestion by a variety of proteases.
The biological function of proteoglycans is to facilitate the packaging of 
proteases within the granules. They remain attached to the protease after the 
granule contents are released. The presence of large protease-proteoglycan 
complexes in the extracellular environment may serve to prevent extensive 
diffusion of the enzymes and enhance their activity by impairing their 
inactivation by inhibitors. The stabilization effect of heparin on human tryptase 
activity may be of crucial importance in mast cell mediated events. Heparin 
also acts as an anticoagulant by enhancing the inhibitory action of antithrombin- 
3, has anti-complement activity and facilitates Hageman factor autoactivation.
1.7.6 Newly Generated Mediators
The mast cell produces several prostaglandins via the cyclo-oxygenase 
pathway of arachidonic acid metabolism. Oxidation of arachidonic acid (5,8,11, 
14-eicosatetraenoic acid) by cyclo-oxygenase gives rise to compounds which are 
collectively called the eicosanoids and includes prostaglandins, prostacyclin and 
the thromboxanes. Another group of eicosanoids, the leukotrienes, are 
synthesized from arachidonic acid by a second enzyme system - the
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lipoxygenase pathway (Samuelson, et al.. 1980). Leukotrienes also appear to 
have a role in inflammation.
1.7.6.1 Eicosanoids; The Biology and Pathophysiology of Eicosanoids in 
Inflammation
Eicosanoids are derived from naturally occurring eicosapolyenoic acids. 
Arachidonic acid, which is either derived from the diet or synthesized from  
linoleic acid, is widely distributed in the body and is usually stored covalently 
bound in its esterified form in the phospholipid fraction of the cell membrane 
of most body cells. Following an inflammatory stimulus, an acylhydrolase, 
phospholipase Av  acts to release the arachidonic acid from its phospholipid 
pool. This free arachidonate is either immediately re-esterified or metabolized 
by one of the two possible enzyme pathways. The cyclooxygenase enzyme 
system w ill convert arachidonate to cyclic endoperoxide - PGG2. This is acted 
upon by another enzyme to yield PGH2, a cyclic hydroxy endoperoxide which 
subsequently gives rise to the primary prostaglandins, PGD^ PGE^ and PGF2 
as well as prostacyclin (PGI2) and non-prostanoate thromboxanes A2 and B2 
(TXA2 and TXB2). Members of this group of eicosanoids have been implicated 
in every phase of inflammation.
1.7.6.2 Cyclo-oxygenase Products
Prostaglandin D 2 is the most important cyclo-oxygenase product of mast 
cells (Lewis et al.. 1982). Human basophils do not produce PGD2. 
Prostaglandin D 2 is also generated by human platelets (Oelz et al., 1977). 
Prostaglandin D 2 in humans is produced by dispersed human lung mast cells 
where there is an approximate 10:1 ratio of T to TC human mast cells (Lewis et 
al., 1982). Prostaglandin D2 is also found in nasal lavage fluid after allergen
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challenge (Creticos et al., 1984). When injected into human skin in nanomolar 
amounts, prostaglandin D 2 causes increased vasodilation and vasopermeability, 
resulting in an erythematous wheal-and-flare reaction similar to that seen with 
histamine, except that it is nonpuritic. The reaction persists for as long as two 
hours and is accompanied by an influx of polymorphonuclear leukocytes. 
When inhaled, prostaglandin D 2 produces bronchoconstriction, w ith a potency 
about 10 times greater than that of histamine (Holgate et al., 1984). That 
prostaglandin D 2 may be an important mediator of anaphylaxis is suggested by 
the finding of markedly increased production of prostaglandin D 2 metabolites 
in the urine of patients with systemic masocytosis who have attacks of flushing 
and severe hypotension (Roberts et al.. 1979). Prostaglandin D 2 is a potent 
inhibitor of platelet aggregation (Mills et al.. 1974).
The other two biologically active cyclo-oxygenase products are prostacyclin 
(a biocyclic prostaglandin) and the thromboxanes, in which a six member oxane 
ring replaces the cyclopentane ring of the prostaglandins. These products, the 
prostanoids, are not stored in situ and several are veiy unstable (Piper et al., 
1971). In aqueous solution at pH 7.5 and 37°C, the half life of cyclic 
endoperoxides PGG2 and PGH2 is 4 and 3.4 minutes respectively before they are 
converted to primary prostaglandins. The half life of PGI2 is 4 minutes and 
TXA2 is 32 seconds (Salmon et al. 1979). PG12 and TXA2 are rapidly hydrolyzed 
to the inactive but stable products 6-keto-PGF and TXB2. Only about 3% of 
PGE2 remains unchanged in the plasma 90 seconds after intravenous 
administration. Release of prostanoids, of which PGE2 is usually predominant, 
is generally accepted to be an integral part of the inflammatory process.
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Prostanoids are also implicated in symptoms involving reactions against 
endotoxins. Prostaglandins are also found in the synovial fluid of human 
patients with arthritic conditions, particularly rheumatoid arthritis. 
Haemodynamic changes attributed to PGI2-induced vasodilation lead to 
systemic hypotension. Low concentrations of PGE! have been shown to cause 
hyperalgesia or enhanced susceptibility to pain, and PGI2 has also been shown 
to be a potentiator of pain responses. Raised concentrations of PGE2 have been 
recovered from cerebrospinal fluids of human patients with high temperatures 
suffering from typhoid/viral encephalitis. The febrile effect is due to an action 
on the anterior hypothallamus and can be blocked by cyclo-oxygenase inhibitors 
(Schwartz, 1987).
1.7.6.3 Lipoxygenase Products
Lipoxygenase enzyme activity in mammalian tissues was first reported 
from platelets by Hamberg and Samuelsson (1974) who showed that arachidonic 
acid could be converted to 12-hydroxyperoxy-5,8,10,14- eicosatetraenoic acid 
(12-HPETE). Turner et al., (1975) demonstrated that 12-hydroxy-5,8,10,14- 
eicosatetraenoic acid (12 HETE), derived from 12-HPETE, was a potent mediator 
for the chemotaxis of polymorphonuclear leukocytes. Walter (1976) showed that 
the accumulation of leukocytes in inflamed tissues was independent of 
cyclo-oxygenase activity. In 1976, Borgeat and co-workers had shown that 
polymorphonuclear leukocytes themselves formed 5-HETE, an isomer of 12 - 
HETE. In  1979 the unstable 5,6-epoxide of arachidonic acid was reported to be 
formed in polymorphs from an open chain hydroxy acid 5-HPETE and named 
leukotriene. The unstable epoxide was given the name leukotriene A4 (LTA4). 
Leukotriene A4 is the most important lipoxygenase product, the first in a series
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of chemical slow reacting substances of anaphylaxis. Leukotriene C4 (LTC4) is 
synthesized inside cells by addition of the tripeptide glutathione (Glu-cys-gly) 
to biologically inactive LTA4. Once secreted, LTC4 can be metabolized 
sequentially to the two other major slow reacting substances of anaphylaxis by 
extracellular enzymes, LTD4 by removal of glutamine and LTE4 by removal of 
glycine. Inactivation occurs by further oxidation and/or removal of cysteine. 
Leukotriene B4 is another important arachidonic acid derivative, a leukotriene 
produced from LTA4 by the enzyme epoxide hydrolase.
In humans, LTC4 can be generated by the dispersed human lung mast cells 
(T:TC mast cells in lung = 10:1) and after cutaneous allergen challenge. Human 
basophils also generate LTC4 (MacGlashan, 1986) as do eosinophils and certain 
macrophages. Leukotriene C4, like LTD4, acts through cell receptors and is a 
potent bronchoconstrictor, enhancing mucus production, increasing vascular 
permeability and acting on vascular smooth muscle. Leukotriene B4 is a potent 
chemotaxin for human neutrophils and is the predominant lipoxygenase 
product of human neutrophils, monocytes and alveolar macrophages.
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CHAPTER TWO
PREGNANCY, IMM UNOLOGY AND ALLERGY
2.1 An Overview of Pregnancy
In  humans, fertilization of the ovum by the sperm and the initiation of 
cell division usually starts in the mid-portion of the fallopian tube. A successful 
pregnancy requires highly synchronised responses including social interactions, 
sexual behaviour and immunomodulatory mechanisms at the various stages of 
pregnancy, orchestrated by the effects of hormones. These processes can be 
broadly divided into three stages:
Stage 1 - the initiation of pregnancy
Stage 2 - the maintenance of pregnancy
Stage 3 - parturation, lactation and maternal behaviour.
2.1.1 The Establishment of Pregnancy
Following fertilization, the embryo remains in the oviductal site for a 
period of three to four days. During this period in the oviduct, the embryo cells 
continue to divide from the two cell to the eight cell stage when the cleaving 
embryo is termed the morula. The morula arrives at the uterus through the 
tubul isthmus. At the 32-64 cell stage, further morphological changes occur 
with the transition of the morula to a blastocyst. Secretions of the uterus 
provide the blastocyst with dissolved oxygen, nutrients and a vehicle for waste 
metabolite removal, permitting its survival. By this time the zona pellucida is 
shed due to activity of the trophoblast. This enables the trophoblast to come 
into direct contact with the endometrium allowing attachment and subsequent 
implantation. Trophoblastic invasion leads to destruction of maternal 
epithelium, connective tissue stroma and also the endothelium of the maternal 
blood vessels, leaving the maternal blood bathing the fetal chorion -
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haemochorial placentation. Thus, fetal tissue is directly exposed to cells of the 
maternal immune system in the maternal blood circulation.
The presence of a fertilised ovum and its subsequent implantation 
provides the mother with a series of signals prominent among which is human 
chorionic gonadotrophin (hCG). This has a luteotrophic function preventing 
luteolysis and maintaining a functional corpus luteum. Progesterone from the 
corpus luteum enables the continuing development of the feto-placental unit. 
Luteal function is maintained until there is sufficient progestagen production by 
the placenta. In  addition to an endocrine function, as the placenta develops it 
takes over as the main organ of nutrition for the fetus.
Thus, the initiation and maintenance of pregnancy is a complex 
physiological event, requiring nutritional, endocrine and immunological 
modulation.
2.1.2 The Mechanisms of Acceptance of the Fetal Allograft - Theories and 
Current Views.
The fetoplacental unit contains a complement of paternally derived 
antigens. W hy then does not the immunocompetent mother reject the fetal 
semi-allograft? A number of mechanisms have been proposed - see paragraphs 
2 .I.2 .I. - 2.1.2.7. below.
A summary of some of the reported changes in the maternal immune 
system during pregnancy are shown in Table 3. (page 31)
2.1.2.1 Lack of expression of paternal M HC and other paternal antigens
Although the fertilised embryo is potentially exposed to maternal 
immune system cells while present in the lumen of the oviduct and uterus, for 
much of this time it is surrounded by the zona pellucida. The initial intimate
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TABLE 3
SUM M ARY OF M ATERNAL IM M U N O LO G IC  CHANGES D U R IN G
PREGNANCY
PARAMETER CHANGE DURING PREGNANCY
Cell counts
Total white countNeutrophilsLymphocytesMonocytesT/B cell ratio
Increased Increased Decreased Increased No change
Neutrophil function Decreased chemotaxis/superoxide anion generation
Immunoglobulins
IgGIgAIgMIgE
DecreasedNo change or slight decrease No changeNo consistent change
Antigen-specific antibody response No change
Autoantibodies
De novo production Preformed RareDecreased (anti-insulin, antithyroid antigens) or unchanged (rheumatoid factor)
Immune complexes Delayed skin tests X4 positive cells
Absent or rareNo change or slight decrease Variable, probably not of biologic significance
In vitro lymphocyte responsiveness
PHAAntigenMixed lymphocyte
Unchanged in majority of studies Conflicting data No change
Pregnancy serum
Effect of lymphocyteresponsiveness to PHA Effect on mixed lymphocyte reactivity
Decreased
Decreased
Mediators of immediate hypersensitivity
Cyclic AMP (urinary) Cyclic GMP (urinary) Histamine Histaminase Prostaglandin Prostaglandin A Prostaglandin E Prostacyclin (I2) Thromboxane A2
IncreasedIncreasedDecreasedIncreasedIncreasedIncreasedIncreased (third trimester)IncreasedIncreased
From, "Principle and Practice of Allergy", Ed. E. Middleton, Jnr, 1985.
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physical contact between mother and fetus occurs at implantation - 
approximately seven days following ovulation, at a time when the trophoblast 
is first forming. At ten or eleven days, the trophoblast differentiates into the 
inner cytotrophoblast and the outer syncytiotrophoblast, a covering layer where 
the cell membranes fuse to produce a multinucleated cell mass. The mature 
placental villus possesses the following layers - at the maternal interface an 
outer layer of degenerated cellular debris, "Roht's" layer; the 
syncytiotrophoblast; the cytotrophoblast; and an inner mesenchymal stroma 
separated from the cytotrophoblast by a basement membrane. Transplacental 
exchange of immunogenic cells and macromolecules can occur in both 
directions, although maternal immunocompetant lymphocytes are usually 
effectively barred from the fetus by the syncytiotrophoblast layer.
The main area of contact between mother and fetus is the trophoblast, 
which expresses paternal antigens. These do not appear to be products of the 
major histocompatibility loci (MHC) or ABO or RH blood group antigens, 
although M HC antigens are present on fetal embryonic cells from around the 
time of implantation and are detectable throughout pregnancy. For this reason, 
the presence of maternal anti-HLA antibodies, which have been demonstrated 
in up to 50% of multigravidous women, do not compromise the success of 
pregnancy. The presence of such antibodies indicate that the normal pregnant 
woman may show immunological reactions against the conceptus. The 
trophoblastic barrier is supplemented by a variety of modifications in  
immunologic responses in both mother and foetus, which allow the pregnancy 
to continue. Factors are present in retroplacental sera which inhibit the 
expression of M HC class 2 antigens on the human monocytic cell line U937 by
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recombinant gamma interferon (Nicholas, et al., 1986). Such factors may at least 
in part be responsible for the lack of M HC class 2 expression by the trophoblast.
2.1.2.2 Antigen masking
The masking of cell surface alloantigens on the trophoblast has been 
proposed as one immunomodulatory factor operating during pregnancy, in 
addtion to the lack of M HC antigen expression on this organ. In  the rabbit, 
uteroglobulin, a 15.8 KDa protein synthesised in the uterus in early pregnancy 
and cross-linked with beta2-microglobulin, results in the masking of M HC  
antigens on the cell surface (Mukherjee et al, 1982). Transferrin bound to 
specific receptors on the trophoblast and IgG bound to trophoblastic Fc 
receptors may have similar masking effect in the human (fohnson et al, 1981).
2.1.2.3 The uterus as an immunologicallv priveleged site.
It has been proposed that the uterus acts as a highly selective site, an 
environment in which the cell mediated immune system is ineffective. Head &  
Gaede (1986) demonstrated la antigen-expressing cells in the uterus of virgin 
rats. Ia antigens are M HC class 2 antigens, expressed presenting cells, and this 
finding suggests that the uterus is capable of local immune responses can be 
decidual and myometrial lymphatic drainage and infiltration can be observed 
adjacent to the trophoblast.
2.1.2.4 The placenta as an Immunological Filter
The fetus and its circulating blood are separated from the maternal 
circulation by the placenta. It has been proposed that the placenta prevents 
immunogenic fetal cell from reaching the maternal circulation thus
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circumventing immunological attack by maternal lymphocytes. However, fetal 
erythrocytes readily cross the placenta.
2.1.2.5 Immunological Tolerance and functional immune deficiency During 
Pregnancy
General or specific maternal immune reponsiveness is maintained with  
only minor alterations during pregnancy. Up to the 20th week of gestation 
there is a fall in the total number of circulating T cells. However, this reduction 
appears to be due to a redistribution of T-cells into different lymphoid 
compartments. An increase in B-cells numbers has been noted, perhaps as a 
compensatory mechanism for the reduction in T-cells (Strelkaukas et al.. 1975). 
The presence of sperm antigens expressed on the early fetus suggests that a 
certain degree of immunological tolerance to paternal antigens may develop in 
pregnant women.
Observations in vitro that cytotxic responses to trophoblast antigens are 
impaired during pregnancy suggest that maternal cell-mediated immune 
responses are impaired. The presence of suppressor cells associated w ith the 
decidua (Clark et at., 1986b) and also the presence of immunoregulatory 
molecules such as pregnancy-specific and pregnancy-associated proteins 
(Sargent & Redman, 1985) are of interest in this context.
A number of observations on cell-mediated immune responses during 
human pregnancy have been published. Hawes et al (1981) studied cell- 
mediated immune responses and skin tests reactions to house dust, house dust 
mite, Candida albicans extracts and tetanus toxoid. The skin test reactions were 
found to be unchanged during pregnancy. However, in vitro lymphocyte 
transformations induced by these antigens were enhanced during pregnancy.
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There is evidence of a pregnancy-associated immune deficiency syndrome 
and the susceptibility to infection by poliomyelitis virus and Plasmodium is two 
to seven times greater in pregnant than in non-pregnant women (Weber &  
Nelson, 1986). The incidence of the following infective diseases is also reported 
to increase in women during pregnancy: hepatitis A, influenza A, variola, 
Entamoeba histolytica infections (Weber & Nelson, 1986).
The diagnosis of carcinoma of the breast is 1.8 times and cervical 
carcinoma 13.5 times more common during pregnancy, although in part this is 
likely to result from the closer clinical supervision of individuals at time. 
Tumours first diagnosed during pregnancy, especially during the third 
trimester, have a poorer prognosis than those diagnosed in the non-pregnant 
state. The five year survival rate of patients with malignant melanoma is 
reduced with each successive pregnancy (Weber &  Nelson, 1986). Although 
these observations may indicate some compromise of other factors including the 
secretion of increased amounts of steroids and other cell growth factors are also 
likely to be an important contributory factor.
Thus, there is some evidence that cell-mediated immunity is depressed 
during pregnancy, but not to a profound degree. Comparative studies on 
pregnant and non-pregnant women related to delayed hypersensitivity, skin test 
responses, skin graft rejection and in vitro stimulation of lymphocytes with 
plant mitogens, recall antigens or allogeneic lymphocytes appear to vary.
The effect of pregnancy on humoral immunity is controversial. Ostensen 
et al (1983) studied humoral immunity in a series of 31 randomly selected 
healthy pregnant women aged 18-36 years, 13 women with definitive or 
probable AJ> aged 22-34 years and 10 patients with RA aged 18-34 years. Levels
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of IgG and IgA were decreased in all pregnant women while IgM  antibodies 
remained normal compared to the non-pregnant state. Multiparous women had 
higher levels of IgG during pregnancy than primigravidae. No differences in 
the frequency of either rheumatoid factor (RF) or antinuclear antibodies (ANF) 
were found when healthy pregnant women were compared to healthy non­
pregnant controls. In another study (Pasca, 1977) serum samples taken at 14 
weeks gestation, at delivery and at 30-45 days post partum revealed that, after 
delivery, humoral immunity to rubella virus returned to the levels of early 
gestation.
Autoimmune diseases show a variable response to pregnancy, although 
the incidence of such diseases in pregnancy is low (Donat, 1986). While 
rheumatoid arthritis (RA) appears to improve in the majority of pregnant 
patients, ankylosing spondylosis (AS) patients generally have unchanged disease 
activity during gestation (CeCere et al, 1981, Bulmarsh, 1979). A postpartum 
disease flare-up occurs commonly in both RA and AS . A decrease in circulating 
immune complexes has been found in RA patients remitting during pregnancy. 
No single serum factor or combination of factors responsible for such gestational 
remission has yet been identified. Generally, however, blood parameters in 
autoimmune patients generally reflect the biochemical changes of a normal 
pregnancy.
2.1.2.6 The Blocking Antibodies of Pregnancy
The significance of the presence of antibodies which may block cell- 
mediated immune responses during pregnancy is a controversial area. In  1964, 
Kaliss and Dagg proposed that successful allogenic pregnancies might be 
protected by such antibodies. Hellstrom et al (1969) suggested that IgG
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antibodies may be the putative blocking factor as these were present in sera 
from primiparous and multiparous mice after allogeneic but not syngeneic 
matings. Blocking antibodies are essential for a normal gestation in the human 
and are absent in the sera of spontaneous aborters - no such antibodies were 
detected in any of a series of eight habitual aborters, whereas all eight normal 
control multiparous women had such antibodies in their sera (Rocklin et al, 
1976). These blocking antibody activities could not be removed by absorption 
to platelets, indicating that the target antigens for these antibodies were not 
HLA -A, -B or -C antigens.
It has been shown that maternal serum can block the cell-mediated 
immune reactivity of maternal cells against paternal antigens in vitro and also 
maternal versus either fetal or paternal mixed lymphocyte reactions (Rocklin et 
al, 1979).
Macrophage migration inhibitory factor (M IF) is a lymphokine produced 
by activated lymphocytes. M IF is produced by maternal lymphocytes in 
response to genetically foreign cells (Rocklin et al, 1973), a response inhibited 
by autologous maternal serum. However, it appears that the blocking factor 
which inhibits M IF release is absent from the serum of chronic habitual aborters 
(Rocklin et al, 1976).
Bell & Billington (1980) reported that female mice produce predominantly 
non-complement fixing IgG antibodies against the fetus during pregnancy. 
Specific antibody production, including IgG antibodies against a number of 
paternal class 1 and 2 HLA antigens, were noted during pregnancy and these 
were shown to be capable of blocking specific maternal cytotoxic lymphocytes 
(Morin-Papunen et al, 1984). Also found are antibody specificities directed
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towards non-HLA antigens produced by the syncytiotrophoblastic layer of the 
placenta - these may combine with the coresponding antigens to form immune 
complexes in the maternal circulation.
Faulk and McIntyre (1983) reported the involvement of non-cytotoxic 
antibodies to the TLX antigens as being of importance in the survival of a 
pregnancy. The TLX antigens are a group of trophpoblast-lymphocyte cross­
reacting molecules closely associated with the HLA antigens. Thus, partners 
sharing common HLA types are likely to have similar TLX antigens and 
consequently are less likely to generate anti-TLX antibodies. They could, 
therefore, be a greater risk of pregnancy loss resulting from such matings. In  
practice it has been found that immunization with paternal cells may reduce the 
rate of pregnancy loss in women suffering recurrent habitual abortion 
(Mowbray et al, 1984). Blocking antibodies to TLX or similar antigens may play 
a role here.
2.1.2.7 Pregnancy Proteins and Immunosupression During Pregnancy
A number of proteins have been identified in human pregnancy. These 
can be classified broadly into two groups: those which are specifically secreted 
during pregnancy (pregnancy-specific proteins); and proteins which are present 
in the non-pregnant state, but found in increased amounts during pregnancy 
(pregnancy-associated proteins). A number of functions have been proposed for 
these pregnancy proteins including suppression of the maternal immune system 
thereby facilitating fetal allograft survival.
The pattern of secretion of pregnancy proteins can be two general types:- 
Pattem A: those present at maximum level during the first few weeks of 
gestation, e.g. human chorionic gonadotrophin, hCG (Braunstein, 1970).
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Pattern B: those the secretion of which appears to relate to the overall 
size of the placenta - levels of these proteins increase throughout 
gestation, often reaching a plateau a few weeks before term, e.g. human 
placental lactogen, hPL (Chard, 1982).
Human chorionic gonadotrophin was the first placental protein identified 
(Ascheim and Zandek, 1927). Human Placental Lactogen (hPL) was isolated 
from pregnancy serum and placenta in 1962 by Josimovich and McLaren. 
Several new placental proteins were described during the early seventies, but 
only a few of these fit the definition of pregnancy proteins in that they are 
synthesised uniquely by the placenta. Chard et al. (1985) reviewed pregnancy 
proteins, suggesting redefinition as "reproductive proteins", dividing them into 
three functional groupings thus:
Group 1 Group 2 Group 3
Enzymes PP5 Binding proteins
hCG,hPL PAPP-A PZP
SP1 PP12
Group 1 products are of trophoblast origin and control mechanisms are 
dependent upon trophoblast mass and uteroplacental blood flow. The 
postulated functions are as hormones and enzymes. Group 2 products are also 
released by the trophoblast and possibly other as yet unidentified sources. 
Postulated functions are activities related to local immunological responses and 
effects on blood coagulation. Group 3 products are of maternal 
hepatic/endom etrial/decidual origin. These are controlled by 
oestrogen/progesterone and bind to small molecules, e.g. thyroxine and 
steroids, as a maternal response to pregnancy.
39
t
There are around forty proteins which have been extracted from placental 
tissues to date. Of those which have been implicated in modulating maternal 
immune responses and which, therefore, could influence allergic reactions, two 
are reviewed below. Table 4 (page 41) shows some soluble placental tissue 
proteins and their characteristics.
2.2 Reproductive proteins potentially implicated in modulating allergic
reactions during pregnancy
Although many of the identified reproductive or pregnancy proteins have 
been ascribed immunomodulatory (usually immunosuppressive) functions, 
reliable experimental evidence has been published for only a few of these. Of 
these, two, pregnancy-associated plasma protein A (PAPP-A) and placental 
protein 14 (PP14), which may potentially influence allergic reactions are 
reviewed here.
2.2.1 Placental Protein 14(PP14)
Placental protein 14 was originally isolated from term placentae (Bohn et 
al., 1982). It is a dimeric 56 KDa glycoprotein with homologous 28 KDa 
subunits (Westwood et al, 1988). It is highly glycosylated (30%) and highly 
hydophobic. The sequence of the first 24 N-terminal amino acids is as follows: 
Met Asp lie Pro Gin Thr Lys Gin Asp Leu Glu Leu Pro Lys Leu Ala Gly Thr 
Glu His Glu Met Ala Met
P14 is a pregnancy-associated protein which is also present in the 
endometrium and peripheral blood of non-pregnant women. Levels increase 
rapidly in early pregnancy - a rise can be detected in the peripheral circulation 
as soon as 2-12 days after embryo replacement in in vitro fertilization (Julkunen 
et al, 1985). Maximal concentrations of the protein appear in the maternal
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TABLE 4
PLACENTALPROTEIN NAME, FUNCTION OR SYNONYM MOLECULARHEIGHT CARBOHYDRATE CONTENT (%)
PP2 Ferritin 500 KDa
PP5 Protease Inhibitor 36.6 KDa 19.8
PP7 Glutathione-transferase 37.1 KDa 5.4
PP12 Chorionic alpha2-microglobulin(CAG-1) 25.2 KDa 4.3
PP14 Chorionic alpha2-microglobulin(CAG-2) 43.0 KDa 17.5
PP15 Immunosuppre s s ive 30.7 KDa 3.3
(Bohn 1985)
41
circulation between 6 and 12 weeks of gestation and decline thereafter. Highest 
levels are found in decidual tissue in which PPM comprises some 10% of the 
total soluble protein by the 7th-8th week of gestation. High levels of PP14 are 
also present in seminal plasma (Bolton et al., 1986a).
PP14 is active in inhibiting T-lymphocyte proliferation in vitro and is 
thought to be an immune regulatory molecule (Bolton et al, 1986b, 1987). 
Indeed, Bolton et al (1987) showed that the immunosuppressive activity of 
decidual tissue can largely be explained in terms of its PP14 content. The 
secretion of PP14 is progesterone dependent (Julkunen et al.. 1986b, Li et al, 
1991). Progesterone itself has been proposed as an important 
immunosuppressive agent in pregnancy as it directly interferes w ith cell-cell 
contact (Clemens et al., 1979) and alters the local exchange of immunological 
information (Van Vlasselaar etal., 1986). However, PP14 does not effect cell-cell 
contact, indicating that the immunosuppressive action of PP14 is independent 
of any shown by progesterone (Pockley & Bolton, 1988).
The mechanism by which PPM appears to act has been investigated in 
some detail. It exhibits an inhibitory effect on Interleukin-2 (IL2) production by 
T-cells (Pockley & Bolton, 1989), probably operating via an inhibitory effect on 
IL-1 production or release (Pockley and Bolton, 1990). The resulting inhibition 
of T-lymphocyte activation and proliferation could potentially have widespread 
effects on the immune system, including modulation of allergic reactions - 
activated T-lymphocytes (CD4+ cells) produce IL4, the lymphokine responsible 
for B-lympocyte proliferation (Stein et al, 1986), differentiation (De France et al, 
1987) and IgE isotype selection (Snapper et al, 1988).
2.2.2 Pregnancy-associated plasma protein-A (PPAP-P)
Pregnancy-associated plasma protein-A is a high M r glycoprotein (750 
KDa)(Lin et al, 1974). An immunosuppressive role for PAPP-A has been 
proposed as it inhibits lectin-induced lymphocyte stimulation (Bischof et al, 
1982). However, such activity has been questioned by Sinsich et al (1984); 
furthrmore PAPP-A shows no suppressive activity in allogeneic mixed 
lymphocyte cultures (McIntyre et al, 1981).
PAPP-A binds to heparin (Sinosich et al, 1981) and inhibits the activity 
of certain proteolytic lysosmal enzymes such as granulocyte elastase (Sinosich 
et al, 1982). Thus, PAPP-A could potentially interfere with the putative role of 
heparin, released from mast cells during allergic reactions, in enhancing local 
protease activity around stimulated mast cells (see page 23).
2.3 Pregnancy and Allergy
The role of allergy in the pregnant state is not well-defined. There is a 
general but apparently unsubstantiated feeling among practising obstertricians 
that allergic conditions improve during pregnancy. Holbreich (1982) in a review  
on asthma and other allergic disorders in pregnancy, described asthma as a 
complicating factor in approximately 1% of all pregnancies. Other allergic 
diseases, such as seasonal rhinitis, vasomotor rhinitis, and urticaria, may occur 
in up to 15% of all pregnancies. It was estimated that asthma w ill improve in 
one third, remain the same in one third and become worse in one third. In  
general, women with severe asthma are more likely to have exacerbations in the 
condition during pregnancy than those with milder disease.
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2.3.1 Asthma in Pregnancy
Gluck and Gluck (1976) reviewed retrospective studies encompassing 
1,087 pregnancies and noted a considerable conflict among these reports 
regarding the influence of pregnancy on the course of asthma. These authors 
also reported that a serum IgE level that increased or remained the same during 
pregnancy tended to be associated with worsening symptoms asthma, although 
this observation was based on data from only 28 patients. In a study from  
Helsinki (Stemius-Aamala et al., 1988), 198 pregnancies in asthmatic women 
were monitored and followed for up to six months postpartum. The patients 
were divided into four groups on the basis of severity as defined by the 
required treatment, and classified as atopic or non-atopic by skin or RAST 
testing. A control group was matched for age, parity and time of delivery. In  
line with previous studies it was found that approximatley 40% required the 
same treatment, 40% required an increase and 20% required a reduction in 
treatment compared to their pre-pregnant state. The most severe groups 
requiring a high dose of medication contained significantly more non-atopic 
cases (those with negetive skin test or RAST) and the majority of these (56%) 
improved after delivery; only 22% improved in the atopic group after delivery.
2.3.2 Allergic rhinitis and pregnancy
Very little has been reported on the effect of pregnancy on allergic 
rhinitis. Nelson (1980) stated that women who have allergic rhinitis may suffer 
worsening of their symptoms during pregnancy, although some women may 
have a Paradoxical improvement of their nasal symptoms. In any case, nasal 
congestion is a common complaint during pregnancy. In one study of 327 
women, 309 complained of frequent or constant nasal symptoms (Mabry, 1980).
44
Eighteen patients had had similar symptoms before pregnancy, but most 
experienced worsening during pregnancy. Congestion of the nasal mucosa 
develops by the end of the first trimester and progresses thereafter. Mucosal 
edema is prominent at the last two months of gestation. Even pregnant women 
without overt nasal symptoms show glandular hyperactivity, increased 
phagocytic activity and increased mucopolysaccharides in ground substance 
(Toppozada, 1982). These changes parallel increases in levels of oestrogen and 
progesterone, which are the probable cause. Paradoxically some women may 
show improvement of chronic rhinitis in pregnancy.
2.3.3 Dermatitis in pregnancy
The effect of pregnancy on atopic dermatitis is unpredictable. Atopic 
dermatitis appears to be largely unchanged during pregnancy. In  one large 
series of patients, 3% showed an improvement and 1% a worsening of 
symptoms, while 96% remained unchanged (Nelson, 1980). Urticaria may be 
limited to or associated with pregnancy and recurrences may occur in 
subsequent pregnancies (Chapman, 1969). Progesterone has been implicated in 
pre-menstrul urticaria, bullous, eczematoid, maculopapular or urticarial lesions 
and immediate or delayed hypersensetivity to progesterone has been 
demostrated (Hart, 1977).
2.3.4 Womb sensitisation and Allergy
Recently, Jacobson(*1990) postulated the womb sensitisation theory in 
allergies. Jacobson reported that some babies who are allergic to cow's m ilk 
had been exposed to high levels of beta-lactoglobulin in utero. Antibodies from
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high level of m ilk protein sensitise the fetus which itself is immuno-competent 
and able to produce IgE anitbodies.
2.3.5 Atopy and Prematurity
Premature babies may be at greater risk of developing asthma and 
eczema than full-term infants. Lucas et al., (1990) investigated 777 infants in a 
multicentre study and noted wheezing or asthma was common in 23 per cent 
and eczema in 19 per cent of pre-term babies. Such findings indicated that pre­
term infants are vunerable to an increased incidence of later allergic reactions. 
Lung damage due to mechanical ventilation in this group is unlikely to be the 
sole reason. This is because wheezing and asthma was noted to be very 
common even in those infants who received no mechanical ventilation at all and 
it was also strongly associated with family history of atopy. Incidence of 
wheezing or asthma was correlated with that of eczema.
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CHAPTER THREE
THE IM M UNOLOGICAL PROCESSES OF 
ALLERGIC RH INITIS
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3.1 Allergic Rhinitis - Clinical Manifestation
Allergic rhinitis or hay fever is defined as a seasonal affliction of eyes, 
throat and nose. Classical symptoms are due to grass pollen and appear in the 
grass pollen season, usually in June and early July in the U.K. In  atopic 
individuals exposure to such allergen manifests, at the initial stage, as itchy red 
eyes, sneezing and dry non-productive cough. In  the second stage secretion 
follows. The eyes water and nose runs. In the lung the cough becomes 
productive and narrowing of bronchi causes diminished airflow resulting in 
bronchospasm. This bronchospasm is clinically manifested as wheezing or 
seasonal asthma. In the third or final stage, oedema causes marked swelling of 
the sclera which, due to secondary infection, often become blood red and exude 
yellowish gelatinous materials. As the cornea is clear, no visual impairment 
occurs. Peripheral involvement of the eyelids result in swelling or blepharitis 
and the conjunctiva takes on a "cobblestone" appearance in severe cases. In  
such cases, if treatment is not available, ulceration may occur resulting in 
irreversible visual impairment. A blocked nose precipitates constant difficulty 
in breathing and chest symptoms may vary from mild discomfort to serious 
asthma.
3.1.1 Patho-phvsiology of Havfever and Asthma
Experimental animals have been used to study the immunological 
mechanisms of asthma, which is the single most important clinical entity of the 
trilogy of atopic diseases. The animals are naturally or artificially sensitised to 
specific antigens to which they are subsequently exposed by inhalation. 
Antigen(allergen)-antibody interaction on the surface of mast cells stimulates the
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release of mediators of asthma attacks. Triggers of allergic reactions are shown 
in Fig. 1, page 49.
Most of the bronchial mast cells are, however, not on the mucosal 
surface, but in the sub-mucosa adjacent to blood vessels and neural ganglia. It 
has been suggested that the antigen binds to the small proportion of sensitised 
mast cells in the bronchial lumen or on the mucosal surface. Access to antigen 
to submucosal mast cells is then enhanced by increased permeability of the 
epithelium, with loosening of the normal "tight junctions" between cells, 
resulting from mast cell mediator release. The reaction is thus amplified (Hogg, 
1978). While this pattern of response is more likely in hayfever asthma among 
atopic individuals, it does not give a clear picture in clinical asthma.
3.1.2 Adrenergic Hypothesis of Reversible Airways Obstruction
The vagus nerve carries both efferent stimuli to the muscle of the 
bronchial tree and afferent information from sensory irritant receptors in the 
airways. Vagal stimulation provokes broncho-constriction via a reflex arc. 
Adrenoreceptors (alpha-receptors) on the bronchial muscles, promote broncho- 
constriction and are constrictors, are few and of doubtful significance; 
beta-receptors, which promote broncho-dilation are much more important. 
These are stimulated naturally by circulating catecholamines. Though the 
presence of adrenoreceptors is now accepted, there is no evidence for a direct 
adrenergic nerve supply to human bronchial smooth muscles. sThe sympathetic 
nerves in the airways are distributed mainly to small vessels and also to 
autonomic ganglia, where their activity may modulate the degree of 
. parasympathetic tone. Szentivamyi (1968) suggested that a state of partial 
beta-blockade may underlie the asthmatic state.
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The demonstration that a pharmacological blockade of beta receptors may 
enhance bronchial reactivity to inhaled allergens or metacholine in hayfever 
patients without a previous history of bronchial asthma is compatible w ith the 
beta-blockade theory.
3.1.3 Cholinergic Hypothesis
Atropine or ipratorium, which is an anti-cholinergic drug, abolishes 
bronchial hyperactivity induced by exposure to various noxious gases, such as 
ozone, nitrogen dioxide or sulphur dioxide, and to bronchial virus infection. 
There may be a similar bronchospasm in hay fever, but here the bronchial 
hyper-activity is less intense, more transient and not associated with  
hypertrophy of the smooth muscle. This gives rise to the suspicion that the 
cholinergic system may be overactive in reversible airways obstruction.
The effects of cholinergic blockade in asthma are variable. In  acute 
challenge with antigen, both in sensitised dogs and in allergic asthmatic 
patients, some studies have shown a complete inhibition of symptoms, while 
others have shown either no protection or only an effect compatible w ith the 
degree of broncho-dilation produced. The effect of histamine is as a direct 
constrictor of bronchial smooth muscle but is also known to stimulate irritant 
receptors and may have an indirect effect via a cholinergic reflex. The role of 
the parasympathetic nervous system is not yet fully understood. However, it 
seems likely to be relevant to the transient acquired hyper-reactivity of normal 
subjects.
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3.1.4 Purinergic Hypothesis
Richardson and Beland (1976) postulate a non-adrenergic inhibitory 
‘'purinergic" nerve supply to the airways. Abnormality of nerves in the 
embryologically-related gastro-intestinal tract have been associated with 
defective smooth muscle function in Hirschsprung's Disease. Whether similar 
nerves supplying the bronchi may be relevant to asthma is not established. 
Another possible contributor to asthma is the reported abnormal permeability 
of the bronchial epithelium, allowing greater access of noxious agents to irritant 
receptors or to the smooth muscle itself.
3.1.5 The Concept of a "Shock Organ"
The idea of a "shock organ" appears to be determined by the site of 
antigen-antibody interactions, for example the skin in local anaphylaxis. 
However, such an idea does not satisfactorily explain why, for instance, one 
person reacts with hayfever and another with asthma to the same inhaled 
allergen. Nor does it explain why the pharmacological hypersensitivity is 
limited to the target cells of one or more tissues instead of affecting all the 
target cells uniformly. In asthmatic patients, for example, the injection of an 
otherwise non-toxic amount of histamine induces wheezing but not hives. In  
urticaria it induces hives, but not wheezing. The ultimate clinical manifestation 
of atopic abnormality, i.e. the organ or tissue localization of the disease, is 
determined by which type is primarily harbouring the postulated abnormality.
3.2.1 Eosinophilia in Allergic Reactions
A conspicuous association of eosinophils with allergic reactions has been 
well-documented but the nature of this association is not clear. Of the
52
catecholamines, both epinephrine and isoprotemon produce eosinophilia, thus 
eosinophilia may be defined as a beta adrenergic action of catecholamines. 
Consequently, an impairment of beta-adrenergic mechanisms would be expected 
to eliminate one of the important suppressing influences in the homeostatic 
control of eosinophils and possibly result in eosinophilia. In a study using 
biopsies of nasal mucus membrane, Lozewicz et al. (1989) reported that 
eosinophil infiltration of mucus membrane occurs at the same time as mast cell 
degranulation.
3.2.2 Newer concepts of the pathogenesis of Allergic Rhinitis
In  Chapter 1, some aspects of inflammatory processes have been discussed. 
Much of this knowledge has been gained using experimental situations and 
animal models. However, in recent times, with the advent of fibre optic 
bronchoscopy and technical advance in tissue fixation procedures, it is now 
possible to study the active physiological and pathological changes occurring 
in human volunteers. The biopsy evidence suggests that inflammation plays a 
fundamental role in the pathology of asthma. Town et al. (1989), Laitiner et al. 
(1985), Djukanvic et al. (1989) have all reported that such inflammation can be 
associated with profound epithelial damage and collagen deposition in the 
submucosa. Roche et al. (1989) reported that the collagen deposited in m ild 
asthmatics is of Type m  and Type V. Roche et al. also reported the presence 
of fibronectin in the lamina reticularis below the basal lamina.
Among recently identified pro-inflammatory mediators are platelet- 
activating factor acether (PAF-acether), free radicals, chemotactic factors, 
eosinophil-derived products, interleukins and a series of neuropeptides. Barnes
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(1989) suggested that bronchial epithelium itself releases a relaxing factor and 
bronchial epithelial cell damage may decrease its release.
3.2.3 Platelet-activating factor acether (PAF-acether)
This is identified as an important mediator of inflammation, which exerts 
a significant effect inducing airway hyper-responsiveness in animals. Recent 
experiments have also shown that PAF can increase non-specific reactivity and 
broncho-constriction in normal human subjects.
PAF is an ether-linked phospholipid released from membrane 
phospholipid by the action of phospholipase A2. It is generated by eosinophils 
(Lee et al., 1984) and alveolar macrophages (Amoux et al., 1983) but not by mast 
cells. PAF acether was first discovered after the observation that lymphocytes 
sensitised with specific IgE antibody and challenged in vitro release a potent 
substance which causes platelet activation (Benveniste et al., 1972). O 'Neill et 
al., (1984) reported alterations to platelet physiology immediately following 
conception in the human caused by a factor which had similar biochemical and 
physiological properties to the potent platelet activating factor l-0-alkyl-2-acetyl- 
yn-glycerol-3 phosphocholine (PAF acether). Embryo-derived PAF may be the 
embryonic factor which signals the presence of a fertilized embryo in the uterus 
during the pre-implantation stages of pregnancy (Orozco et al. 1986). PAF is 
also a potent chemotactic factor for eosinophils and preactivates them for 
mediator release (Wardlow and Kay, 1986).
3.2.4 Oxygen Radicals
Oxygen is used in human metabolism to transform nutrients to energy, to 
oxidise endogenous compounds and to detoxify xenobiotics. These processes
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generally transform stable molecule oxygen (0 2) to stable reduced states, such 
as C02 and H 20 . In the process four electrons are added to each oxygen 
molecule. Under certain circumstances, however, the reduction of oxygen may 
be incomplete, yielding a series of unstable oxygen species, including oxygen- 
derived free radicals (ODFR) 02' (Superoxide) and OH (Hydroxyl). During 
inflammation, polymorphonuclear leucocytes and cells of the monocyte/ 
macrophage lineage elaborate superoxide when activated (Babior 1978). This 
normally serves to lyse invading cells, to alter permeability of endothelium and 
to generate a chemotactic factor from a plasma-derived substrate, thereby 
defending the host against infection (Joyce, 1987).
Defects exist in superoxide production by leucocytes. Hereditary defects 
also exist in the cellular mechanisms which protect against ODFR, for example 
glucose-6-phosphate dehydrogenase deficiency. The resulting increase in 
concentration of ODFR leads to accelerated haemolysis and ODFR have also 
been implicated in altered vascular permeability and disturbing smooth muscle 
calcium homeostasis.
3.2.5 Lvmphokines
Lymphokines, particularly IL4, are of particular interest in patients 
suffering from hyper IgE syndrome and also in some atopic individuals 
(Callard, 1987). IgE responses in the human can be obtained by B cell 
stimulation with IL4 secreting T-cell clones (Maggi et al.. 1988). Soluble CD23 
(sCD23) has been found to enhance ongoing IgE secretion by B-cells from atopic 
patients. IL4 is a potent stimulant of IgG l as well as IgE production (Paul, 
1987), and also stimulates Ig Class switching. Heiner (1984) reported that 
properties of IgG l and IgG4 are similar in certain respects and specific
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combined deficiencies tend to be associated with certain diseases. It is possible 
that IL4 exerts significant effects as a growth and differentiation factor in atopic 
individuals.
3.3.1 Hayfever Distribution and the Dimension of the Problem
Hayfever is the commonest allergic disease in the U.K. and affects 
approximately ten percent of the population - one in four of the participants 
surveyed by "Which?" Magazine in 1985 reported a history of hayfever 
symptoms in the household. It has been reported that among the general public 
nearly one in five professional people suffer from hayfever compared with only 
one in ten of the general population. There are regional variations of incidence 
among the UK population. The condition usually occurs in childhood or early 
adult life, but it can arise for the first time in middle age. In  a survey among 
the general public it was found that symptoms generally manifested before the 
age of 15 and were suffered for 17 years on average. Both sexes are equally 
affected. Some people grow out of their hayfever symptoms in their late 
twenties, thirties or forties, although it may return later in life.
It is estimated that about 30 to 40 per cent of hayfever sufferers get 
summer asthma and each year a quarter of a million people are obliged to be 
absent from work from hayfever. Among known asthmatics, 30 per cent are 
incapacitated occasionally and 15 per cent frequently during the hayfever season 
(Lane &  Starr, 1979).
The weather has a particular influence upon the incidence of hayfever by 
affecting the release of pollen into the atmosphere and the subsequent increase 
in pollen count. For example, due to the sudden burst of hot weather in late 
June 1983, there occurred a rise above the expected rates of non-infective
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wheeze and the dry, sunny April in 1984 produced a similar rise ("Doctor”, May 
1984).
3.3.2 Allergens
All allergens were thought to be functionally identical, acting 
non-specifically on the same sensitive target common to all atopic people. 
However, isolation of house dust allergen did not confirm chemically that there 
is a unique allergen molecule and many distant allergens have now been 
identified.
Allergens are mostly brown in aqueous solution, thermostable, resistant to 
proteolytic digestion and weakly immunogenic in laboratory animals. They 
migrate fast anodically in an electric field at slightly alkaline pH, and are 
relatively deficient in free amino groups. In the semi-solid state, allergens are 
highly hygroscopic.
3.3.3 Pollen Allergens
Pollen extracts (March et al., 1970) contain a number of distinct groups of 
antigenically different allergenic glycoproteins displaying immunochemical and 
allergological cross-reactivity only within each group. Pollen grains are 
generally between 12 and 25 microns in size and the molecular weight of pollen 
allergens is usually in the order of 20 KDa. Clinical and immunological 
evidence confirms that, apart from a general response to allergenic 
determinants, the body reacts to these particular allergens by the production of 
specific antibody directed against the antigenic determinants.
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TABLE 5. Biological Properties of Timothy Grass Pollen
Family - Graminae.
Sub family - Festucoideae.
Tribe - Agrostideae.
Allergen number - 28.
Allergen group - B (mol. wt. 19,000 and under).
Antigen content - Group I antigen.
Antigen B only found in Timothy.
Allergen 19 and 25 with molecular weight 15,000 account for 
85% of total allergenicity.
Electrophoretic migration velocity: positive in relation to 
human albumin.
Analysis of 11 of the 28 antigens were shown to be allergic 
to human.
Protein determination shows antigen No. 3,19,24 as pure amino 
acids and others to be glycoproteins.
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3.3.4 Timothy Grass (Phleum pratensel Pollen
Timothy grass is common throughout the British Isles, occurring naturally 
in meadows. Pollination occurs in July. Timothy grass allergen cross-reacts 
with many other grass pollens, making this a particularly useful species for 
study. Table 5 shows the biological properties of Timothy grass pollens.
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AIMS OF THE STUDY
(a) To investigate and determine the levels of total and allergen-specific IgG4 
and IgE in non-atopic and atopic patients during pregnancy and to 
compare these levels with those in the same patients after pregnancy.
(b) To correlate the laboratory findings with that of clinical manifestations of 
allergic symptoms.
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CHAPTER FOUR 
PATIENTS AND CLINICAL METHODS
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4.1 Study Location
This project was undertaken at the Langold Health Centre, Worksop in 
Nottinghamshire. The Health Centre cares for a population of 7000 patients. 
Almost the entire population is of European stock. Most of the patients are in 
the mining industry and some are involved in agriculture and professions, e.g. 
teachers, office workers, etc. The practice area is surrounded by agricultural 
lands and woodlands.
4.2 Preliminary Environmental Survey
It is well established that clinical manifestations of hayfever relate to 
environmental factors, particularly the pollen count. A preliminary survey was 
carried out to investigate the environmental factors pollen count, rainfall and 
temperature and also to identify the principal plant species known to generate 
allergenic pollen found in the geographical location of the clinical study area.
The local pollen counts, obtained from the National Pollen Count Centre 
at Rotherham - 10 miles north of Langold, were analyzed for three consecutive 
years during the pollen seasons in 1984, 1985 and 1986 (Appendix I). Fig. 2, 
Appendix I, shows monthly pollen count, rainfall and temperature from May 
to August 1985.
The principal allergic pollen-generating species in the area are shown in 
Appendix I. It can be seen that the parishes from which the practice population 
are drawn contain over 1000 ha of grassland and it was thus likely that grass 
pollen would be a common allergen in this population.
4.3 Preliminary Patient Selection
A preliminary survey was undertaken to determine the most common 
allergen affecting the population so that this could be examined in the
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subsequent study of pregnancy. This preliminary study also enabled a clear 
understanding of the clinical manifestations of hayfever and of any significant 
local variations to be obtained. It also provided a basis for a comparison of the 
clinical symptoms in the pregnant and non-pregnant population. Practice 
hayfever sufferers were invited to join the preliminary study. In  response to a 
notification that allergy screening facilities were available in the practice, a total 
of 75 known hayfever patients attended for allergy screening.
4.4 Diagnostic Procedures 
Clinical History
In  allergy, as in any other branch of medicine, history taking is all 
important. In  order to achieve an accurate history comparable between 
individual cases and to arrive at a clear presumptive diagnosis, an allergy case 
history from (Form 1, Appendix II) was designed.
Clinical Examination
This included a general examination with special attention to chest 
symptoms such as asthma, nasal polyp, deviated nasal septum and eczema 
lesions.
Skin Testing
For the purpose of identification of local allergen distribution among the 
practice population and also for the identification of a model allergen for further 
laboratory investigations, the modified skin prick test was used.
A single drop of allergen extract was placed on the skin, on the inside of 
the forearm. Allergen testing solutions were prepared from aqueous allergen 
extracts containing 50 per cent glycerin and 0.4 per cent phenol in 3 ml dropper 
bottles. These solutions are standardised by the manufacturers by iso-electric
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focusing to ensure constant potency and reproducible results. Allergy 
concentrations are quoted as protein nitrogen units (PNU) per unit volume. The 
allergen was dissolved in normal saline and a stilette introduced through the 
drop of allergen into the skin at an acute angle and followed by a single vertical 
lift. Test solutions were separated from each other and results were compared 
with negative and positive controls. The responses, which appeared as wheals 
of different sizes, were evaluated after 10 to 20 minutes. The results recorded 
on form II I  (Appendix II). Skin test kits were produced and provided by E. 
Merck Pharmaceuticals, Alton, U.K.
Interpretation of Results of Skin Test
The wheals were graded as either +, ++, +++, ++++, or +++++, according 
to diameter (Table 6). In order to avoid confusion and operator error, these 
tests were carried out by a single operator.
4.5 Summary of Results of Preliminary Screening
The study was conducted in a rural setting in England covering a 
population of approximately 7000 people. Pollen counts in the summer months 
of three consecutive years showed that June 1984 and June 1986 had similar 
daily average pollen count of 103 where as June 1985 had an average pollen 
count of 62 for the same period.
A total of seventy five patients with allergic symptoms attended for 
preliminary screening (Table 7). Forty two of these were male and thirty three 
were female. Among the male patients, seven suffered from perennial 
symptoms, twenty eight with seasonal symptoms and seven with perennial 
symptoms with seasonal exacerbations. Among the female patients, ten had 
perennial symptoms, twenty one seasonal and two reported seasonal 
exacerbation of symptoms.
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Extracts of thirty two different allergens were tested, depending on the 
history of individual allergic symptoms. The top three positive reactions to 
plant pollens were against grass (54) barley (35) and wheat (19). Appendix I I I 
Table 8 shows the distribution of skin test reactions.
The age of onset of symptoms in the attendant group was reported to be 
from the very young (under 2 years of age) up to the age of 48 years (Appendix 
ID Tables 9 and 10).
Appendix I I I  gives full details of the patients screened and the results of 
the skin tests.
Skin testing confirmed grass pollen to be the most common allergen among 
the test population. Phadebas IgE PRIST (Pharmacia) and IgE R AST (Pharmacia) 
tests were employed for quantitative determination of immunoglobulins against 
Timothy grass allergen which was confirmed to be present in all twelve test 
samples randomly taken from the selected patient group with allergic symptoms.
4.6 The Selection of Pregnant Patients
Pregnant women were initially interviewed while attending the antenatal 
clinic, collecting the data using Form n, Appendix II. Appropriate individuals 
were entered into the study. No skin tests were carried out on these women to 
avoid potential detrimental effects of such procedures during pregnancy. Also, 
the interpretation of skin test results are likely to be anomalous in pregnancy. 
Patients participating in the study were requested to record their own allergic 
symptoms daily using Form IV  (Appendix II).
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TABLE 6. Assessment of skin test reactions by the prick test.
TABLE 7.
+ A raised weal of diameter up to 3 mm
++ A raised weal of diameter from 3 to 8 mm
+++ A raised weal of diameter from 8 mm to 16 mm
++++ A raised weal of diameter from 16 mm to 20 mm
+++++ A raised weal of diameter of greater than 20 mm
N u m b e r  a n d  s e x  o f  a l l e r g y  p a t i e n t s  a t t e n d i n g  f o r  s k i n  t e s t .
SEX PERENNIAL SEASONAL SEASONAL AND PERENNIAL TOTAL
Male 7 28 7 42
Female 10 21 2 33
Total 17 49 9 75
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The groups selected for study were:
Group 1 Pregnant Allergic N = 18
Group 2 Pregnant Non-allergic N = 16
Group 3 Non-pregnant Allergic N = 15
Group 4 Non-pregnant Non-allergic N = 18
Participating patients joined the study voluntarily. 
Blood samples were collected at about 10 weeks and at 32-36 
weeks of pregnancy. Follow-up specimens were collected at 
6 weeks and about 6 months following delivery.
68
CHAPTER FIVE 
LABORATORY MATERIALS AND METHODS
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5.1.1 Specimen Collection and Storage
Blood samples (10 ml) were collected in plain containers by venipuncture 
from each of the four groups of individuals as defined below: - 
Group 1 - pregnant allergic women;
Group 2 - pregnant non-allergic women;
Group 3 - age matched non-pregnant allergic women;
Group 4 - non-pregnant, non-allergic women.
The specimens were allowed to clot for 1 hour at room temperature, followed 
by centrifugation at 700 x g for 10 min at room temperature. The serum was 
stored at -20°C until tested.
5.1.2 Assay Method. Enzyme-linked Immunosorbent Assay 
Commercial assay kits were used to measure the levels of
allergen-specific circulating IgE (Phadezym PRIST™, Pharmacia Biotecnology) 
and IgG4 (RAST™, Pharmacia Biotechnology) antibodies. These immunoassay 
systems are based on the principle of the allergosorbent test. Details of the 
reagents provided are given in Appendix IV.
5.1.3 Principle of the Procedure for the Determination of Circulating 
Allergen-Specific IgE
The allergen of interest (Timothy grass pollen), covalently coupled to a
paper disc, reacts with specific IgE in the patient serum sample. After washing,
a disc-allergen-IgE complex remains. Anti-IgE, conjugated with the enzyme B-
galactosidase via a thiol sensitive disulphide link, reacts w ith any IgE bound to
allergen on the disc. After washing away surplus loosely adsorbed reagent, a
disc-allergen-IgE-anti-IgE enzyme complex remains. The enzyme is released
from the complex by the addition of glutathione. The enzyme then reacts with
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the chromogenic substrate O-nitro-phenyl-B-galactoside to form a yellow- 
coloured product, O-nitrophenol, and colourless galactose. The enzymatic 
hydrolysis is stopped after a fixed reaction time by addition of sodium 
carbonate. The absorbance measured at 420 nm is directly proportional to the 
concentration of enzyme bound to the allergen disc and hence to the level of 
allergen-specific IgE.
5.1.4 Test Procedure
Details of the reagents supplied for this assay are given in Appendix IV. 
The paper discs with bound specific allergen were incubated with the test sera 
at room temperature for three hours. The discs were then washed three times 
with the washing solution. A solution of anti human-IgE enzyme complex was 
added and the incubation continued overnight at room temperature. Discs were 
then washed three more times after which the development solution, containing 
enzyme substrate, was added to all tubes. Tubes were covered with plastic film  
and incubated at 37°C for 2 hours exactly. The reaction was then terminated by 
adding stop solution and the absorbance of the coloured product was measured 
at 420 nm using an LKB spectrophotometer.
5.1.5 Calculation of Results
The absorbance value of each reference serum and unknown sample was
measured. Results were expressed as a percentage of the reference serum
response (units - PRU/m l) by calculating:-
X absorbance of unknown
----------------------------------------------------------  x 100
X absorbance of reference
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5.1.6 Principle and Procedure for the Determination of Total Serum IgE 
The IgE PRIST™ (Paper Radioimmunosorbent Test) is based on the
standard sandwich immunoassay technique using paper discs as a solid phase. 
Anti-IgE, covalently coupled to the paper disc, is allowed to react during the 
first incubation with the IgE in the sample. After washing, a fixed amount of 
enzyme-labelled anti-antibody is added, which forms a complex w ith the IgE 
molecules bound to the paper disc during the first incubation. Bound and free 
anti-human IgE-enzyme complex are separated by washing the disc. After 
incubation with the developing agent containing the enzyme substrate and 
stopping the reaction, the absorbance of the yellow coloured product is 
measured at 420 nm. The colour is directly proportional to the concentration 
of IgE antibodies in the sample.
Each determination was performed in duplicate.
5.1.7 Test Procedure
Patient samples were diluted 10 fold with sample diluent (horse serum). 
A standard curve was prepared for each individual assay.
Details of the reagents supplied for this assay are given in Appendix IV . 
Paper discs containing sheep-anti-IgE were incubated with the test sera at room 
temperature for 3 hours. The discs were then washed three times w ith washing 
solution. Enzyme-labelled rabbit anti-human IgE solution was then added and 
incubated overnight at room temperature. Discs were washed three more times 
after which the development solution containing the chromogenic substrate 0- 
nitro-phenyl-B-galactoside was added. The reaction was allowed to continue 
for exactly 60 minutes at 37°C and then terminated by stop solution (sodium
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carbonate). Measurement of the absorbance of the coloured product of the 
enzyme hydrolysis (O-nitrophenol) was carried out using an LKB 
spectrophotometer.
The results were calculated as described in paragraph 5.1.5 above.
5.2.1 Principle and Procedure for the Determination of Circulating Specific
IgG4.
In  the IgG RAST™ assay, the specific allergen (Timothy grass pollen) 
covalently coupled to the walls of plastic tubes reacts with the corresponding 
specific IgG in the patient serum sample. After washing away loosely adsorbed 
non-specific IgG, enzyme-labelled mouse monoclonal antibodies against human 
IgG4 are added. After washing, the enzyme is released from the complex and 
is quantitated as indicated above (paragraph 5.1.3). To evaluate the test results, 
absorbance values of patients' serum are compared directly with the absorbance 
value of a reference serum run in parallel.
5.2.2 Test Procedures
Patient serum samples were diluted 1:50 with sample diluent (containing 
chicken serum in buffer solution) supplied by the manufacturers of the test kits 
(Pharmacia Biotechnology).
After washing the allergen coated tubes, 100 ul of reference sera or 
diluted patient serum samples were added to appropriate tubes and allowed to 
incubate for 3 hours at room temperature. Tubes were washed 3 times, w ith 10 
ml of wash buffer and 100 ul of enzyme-labelled mouse anti-human IgG4 was 
then added to all tubes except the blanks. The reaction tubes were allowed to 
incubate overnight at room temperature after which they were washed a further
3 times as above. 200 ul aliquots of development solution (O-nitrophenyl-B- 
galactoside and glutathione) were then added to all tubes including the blanks. 
Following a further incubation of exactly 30 minutes at 37°C, 1 ml stop solution 
(sodium carbonate) was added to all tubes.
The absorbance of the coloured product was measured at 420 nm using 
an LKB spectrophotometer.
Results were expressed as a percentage of the reference 
response by calculating:
Mean absorbance unknown 
--------------------------------------------------------  x 100
Mean absorbance reference
5.3.1 Principle and Procedure for the Determination of Total IgG and Total
Sub-class IgG4
The Radial Immunodiffusion (RID) Assay
The determination of a soluble antigen by radial immunodiffusion 
involves antigen diffusing from a cylindrical well through the liquid phase of 
an agarose gel. When the corresponding antibody is uniformly incorporated in 
the gel, immunoprecipitation w ill occur when the antigen diffusing outward 
reaches the concentration of equivalence with the antibody. The end point is 
reached when all of the antigen has reacted with the antibody forming a 
precipitation ring. The diameter of the precipitation ring is proportional to the 
antigen concentration, thus a standard curve may be generated by plotting the 
ring diameters of a number of standard solutions versus their concentrations. 
The concentration of the antigen in an unknown sample may then be 
determined by measuring the diameter of the ring produced by that sample and 
interpolating this value into the standard curve. The measurement may be
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made after a fixed diffusion time or after equilibrium has been reached. In  the 
present study, measurements were taken after equilibrium.
5.3.2 Specimen Preparation
Serum samples were collected as described in paragraph 5.1.1 above. The 
total IgG concentration of the samples was determined using undiluted patient 
serum according to the manufacturers instructions (The Binding Site Ltd., 
Birmingham, UK). For the measurement of total IgG4, serum samples were 
diluted 1:2 w ith the sheep serum included in the kit.
High, medium and low concentration calibrators or standards are 
supplied with each kit. These were reconstituted to the stated volume with  
distilled water. Each calibrator contains 0.2% sodium azide as a preservative 
and is physically and chemically similar to normal serum.
5.3.3 Procedure
Following removal of the lids, the RID plates were stood at room 
temperature for 10 mins to allow evaporation of any condensation.
The amount of antibody in each batch of plates is identical so that a 
calibration curve does not need to be made for each plate. 5 ul of calibrator in 
sample was added to each well in the plate using a Hamilton microsyringe. 
The plate lid was tightly closed and the assay was allowed to run to completion 
(48 hours for IgG and 96 hours for IgG4). The diameter of the rings measured. 
For maximal accuracy the rings must be allowed to diffuse to full size, a final 
ring size for the high calibrator of between 8.7 -9.3 mm being acceptable. Any 
reading outside this size was ignored and the tests were repeated. The
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concentrations of protein were read from the R ID reference table supplied with 
the assay, taking into account any dilution factor.
5.3.4 Calculation of Results
After completion of the assay ring diameters were measured using the 
calliper provided with the R ID Reference Table. The total IgG and IgG4 
subclass concentrations were then read directly from the appropriate column.
Using the same batch of plates, three sets of calibrators were run. A 
typical standard calibration curve for total IgG is shown in Fig. 3. A ll tests were 
completed under similar conditions as recommended by the manufacturers.
The between assay precision for the RID assays, using a pool of blood 
from non-pregnant females in 18 assays was:
IgG (total) - Mean = 9.06 g/1
- SD = 1.57 g/1
- CV = 17.3%
IgG4 - Mean = 223 mg/1
- SD = 4 3  mg/1
- CV = 19.3%
These values compare with the manufacturers figures of coefficients of variation 
of 17% for IgG and 28.5% for IgG4.
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Mean, Standard Deviation and Coefficient Variation are shown in Table 11 A. 
lese results are discussed in full detail in Chapter Six. 
able 11A
IgG TOTAL
MEAN SD CV%
1. Pregnant-Allergic Women 9046 2550 28% n=48
2. Pregnant Non-Allergic Women 9408 2199 23% n=34
3. Non-pregnant Allergic Women 9364 1797 19% n=15
4. Non-pregnant Non-allergic Women 9063 1566 17% n=18
Female Single Donors 10402 1768 17% n=60
IgG4 (TOTAL1
MEAN SD CV%
1. Pregnant-Allergic Women 320 224 70% n=46
2. Pregnant Non-Allergic Women 486 203 42% n=32
3. Non-pregnant Allergic Women 351 181 52% n=15
4. Non-pregnant Non-allergic Women 223 43 19% n=18
Female Single Donors 321 192 60% n=53
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6. INTRODUCTION
Sufficient immunoglobulin data for subsequent analysis were obtained 
from a total of 67 individuals. Of these 18 were pregnant women who suffered 
allergic symptoms (pregnant allergic), 16 were pregnant women who suffered 
no such symptoms (pregnant non-allergic), 15 were non-pregnant women who 
suffered allergic symptoms (non-pregnant allergic) and 18 women were not 
pregnant and suffered no allergic symptoms (non-pregnant non-allergic).
6.1 Changes in serum concentrations of immunoglobulins during pregnancy
in allergic and non-allergic women
The data on the 67 individuals were analyzed using the SPSS /P C  + V 3.1 
statistical package, which was also used to generate graphical representations 
of the data. Advice on statistical methods and their interpretation was provided 
by the Trent Regional Health Authority Statistical Unit, Sheffield ( S. Saljano).
6.1.1 Description of the data used in the analysis
(a) Nature of the data
Data were obtained from 4 experimental groups thus:
Group 1 - pregnant allergic (n=18)
Group 2 - pregnant non-allergic (n=16)
Group 3 - non-pregnant allergic (n=15)
Group 4 - non-pregnant non-allergic (n=18)
Five serum immunoglobulin measurements were recorded for each woman: 
Total immunoglobulin G [IgG (total)]
Total immunoglobulin G subclass 4 [IgG4 (total)]
Timothy grass antigen-specific IgG4 [IgG4 (a-s)]
Total immunoglobulin E [IgE (total)]
Timothy grass antigen-specific IgE [IgE (a-s)]
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A single blood sample was taken from the women in Groups 3 &  4 for 
immunoglobulin measurements. These samples were collected in April 1986. 
Four blood samples were taken for immunoglobulin measurements from the 
women in Groups 1 & 2. These were taken at times after the beginning of the 
pregnancy and, therefore, they also exhibited seasonal differences. These can 
be summarized thus:
Stage A - early pregnancy (7 weeks + /-  3), season 1 (February - April). 
Stage B - late pregnancy (33 weeks + /-  3), season 2 (May - July).
Stage C - first post-natal (six weeks after delivery) - season 3 (August - 
October).
Stage D  - second post-natal (36 weeks + /-  3 after delivery) - season 4 
(November - January).
An additional data item recorded was the parity of each of the pregnant 
women. These data are summarised in Table 12, a-d.
(b) Completeness of the data
The immunoglobulin data for Groups 3 & 4 are complete. For the pregnant 
women (Groups 1 & 2) some measurements are missing, particularly for the 
second post-natal measurement (Stage D).
(c) Undetectable levels
Undetectable levels are shown as less than the defined minimum detectable 
levels of each assay. These were: 
for IgE (a-s) - <0.35 PRU/m l 
for IgE (total) - <5 kU/1 
for IgG4 (a-s) - <5 per cent
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Table 12. The concentration of various immunoglobulins in the peripheral
blood taken from pregnant allergic, pregnant non-allergic. non-pregnant allergic 
and non-pregnant non-allergic women.
Units
IgE (a-s) - PRU/m l 
IgE (total) - kU/1 
IgG (total) - g/1 
IgG4 (total) - mg/1
IgG4 (a-s) - % of response of reference serum
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(d) Derivation of a single immunoglobulin measurement for the pregnant 
women (Groups 1 & 2)
In  order to compare the pregnant women in Groups 1 & 2 w ith the non­
pregnant women in Groups 3 & 4 a composite single set of immunoglobulin 
measurements is required for each such woman. The average concentration of 
each immunoglobulin in samples taken at Stages A to C of pregnancy (ie from  
10 weeks gestation - 6 weeks post partum) was used to derive a single 
measurement for each immunoglobulin for each pregnant woman. The second 
post natal sample (Stage D) was not used to derive this composite value as few  
measurements were available and also these samples were taken 6 months after 
the end of the pregnancy. This composite average value used as much data as 
was available for each individual. Thus, if only a single measurement was 
available in an individual pregnancy, this value was taken. If  two or three 
values were available, these were meaned.
6.1.2 Statistical analysis of the immunoglobulin measurement data
The statistical analyses used were two-way analysis of variance 
(ANOVA), two sample T-tests, matched pairs T-test and repeated measures 
ANOVA. These techniques require the data to conform to the following 
assumptions:
1. Data for each immunoglobulin measurement within each of the four 
groups of women should be approximately normally distributed.
2. The variance of the data for each immunoglobulin measurement 
within each of the four groups of women should be approximately equal.
If  it appears that these assumptions are violated then the data should be 
transformed.
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Table 12a. Levels of Immunoglobulins in pregnant allergic women
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Table 12b. Levels of Immunoglobulins in Pregnant Non-Allergic Women
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Table 12d. Levels of Immunoglobulins in Non-Pregnant Non-Allerqic Women
m
8
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Table 13a. Summary of Means, Standard Deviation and 95% Confidence Intervals.
A IgE (A-S)Means and Standard Deviations
M e a n S t d .  D e v . N 95 % C o n f I n t e r v a l
P R E G N A N T  A L L E R G I C 1.22 2.72 14 0.68 2.17
P R E G N A N T  N O N - A L L E R G I C — — 1 — —
N O N - P R E G N A N T  A L L E R G I C 17.48 4.45 15 7.64 40.00
N O N - P R E G N A N T  N O N - A L L E R G I C 1
” ”
F o r  e n t i r e  s a m p l e 4.20 6.46 31 2.12 8.33
B I g E  ( T o t a l )
M e a n s  a n d  S t a n d a r d  D e v i a t i o n s
M e a n S t d .  D e v . N 95 % C o n f I n t e r v a l
PREGNANT ALLERGIC 103.2 3.3 18 57.3 186.0PREGNANT NON-ALLERGIC 12.6 2.0 15 8.6 18.3NON-PREGNANT ALLERGIC 200.3 2.2 15 129.4 309.8NON-PREGNANT NON-ALLERGIC 23.5 1.8 15 17.0 32.7
For entire sample 51.5 4.0 63 36.3 73.0
C IgG (Total)Means and Standard Deviations
Mean Std. Dev. N 95 % Conf Interval
PREGNANT ALLERGIC 9083 2185 18 7996 10169PREGNANT NON-ALLERGIC 9392 1980 16 8337 10447NON-PREGNANT ALLERGIC 9364 1797 15 8369 10359NON-PREGNANT NON-ALLERGIC 9063 1566 18 8285 9842
For entire sample 
(Total)and Standard Deviations
9214 1860 67 8761 9668
Mean Std., Dev. N 95 % Conf Interval
PREGNANT ALLERGIC 396 219 16 279 513PREGNANT NON-ALLERGIC 473 188 12 353 592NON-PREGNANT ALLERGIC 351 181 15 251 451NON-PREGNANT NON-ALLERGIC 224 43 18 202 245
For entire sample 349 187 61 301 397
E IgG4 (A-S)Means and Standard Deviations
Mean Std. Dev. N 95 % Conf Interval
PREGNANT ALLERGIC 11.73 657.46 18 10.34 13.52PREGNANT NON-ALLERGIC 13.13 229.57 16 10.34 17.22NON-PREGNANT ALLERGIC 16.66 297.27 15 13.03 22.04NON-PREGNANT NON-ALLERGIC 17.65 416.49 18 14.57 22.04
For entire sample 14.46 307.79 67 13.03 16.13
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* 6.1.2.1 Evaluation of the assumption of a normal distribution of the 
untransformed immunoglobulin data
For each immunoglobulin, and for each of the four groups of women, 
normal probability plots were visually inspected to check normality. In  a 
normal probability plot each observed value is plotted against its expected value 
from a normal distribution. If the sample is from a normal distribution the 
points should fall, more or less, on a straight line.
Initially, such a visual evaluation was carried out and a total of 32 plots 
reviewed. The visual inspection revealed that the observed and expected points 
for the groups of women did not cluster around a straight line in all cases.
This subjective, visual assessment of the data was further investigated 
using the Lilliefors test which provides a test of the null hypothesis that the 
data are from a normal distribution. This test confirmed that the untransformed 
data for IgG (total) and IgG4 (total) showed a normal distribution.
6.1.2.2 Evaluation of the assumption of equality of variance of the
untransformed immunoglobulin data.
The Levene test for the homogeneity of variance is particularly useful in 
evaluating whether data are suitable for use with ANOVA procedures. The 
results of this analysis showed that the untransformed data for IgE (a-s), IgE 
(total) and IgG4 (total) did not conform to the assumption of homogeneity of 
variance.
In  the case of IgE (a-s), IgE (total) and IgG4 (a-s), where the assumptions 
of either normality of distribution or equality of variance were not valid, the 
data were transformed.
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6.1.2.3 Determination of the required transformation
A power transformation is frequently used to stabilise variances and also 
quite often overcomes departures from normality. Of the data from the five 
immunoglobulin measurements in Sections 6.1.2.1 and 6.1.2.2 above, only the 
values for IgG (total) conformed to both assumptions of normality and equality 
of variance.
Various power transformations for the data of the other four 
immunoglobulins were investigated. The significance levels of the Levene and 
Lilliefors statistic for the transformed variable were compared with their 
untransformed equivalents. A ll transformations for IgG4 (total) were rejected 
as the inequality of variance was not corrected and non-normal data were 
generated.
Following this analysis, subsequent statistical studies were based on the 
following:
For IgE (a-s) - natural logarithm
For IgE (total) - natural logarithm
For IgG4 (a-s) - reciprocal of the square root.
The data for IgG (total) and IgG4 (total) were analyzed untransformed. 
A summary of the means, standard deviations and 95% confidence intervals for 
these data are given in Table 13, A-E. It should be noted that, in the case of 
the transformed data, the values of the means and confidence intervals given 
in Table 13 a-e were obtained by applying the inverse transformation to convert 
them back to the original units of measurement. Thus, the standard deviations 
quoted in this Table have no meaning in the untransformed state when 
transformed data have been analyzed.
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6.1.3 Comparisons of immunoglobulin concentrations
A two sample T-test was carried out for paired group comparisons 
within each set of immunoglobulin data. A p value of less than 0.05 indicates 
that the mean immunoglobulin concentrations of the two groups are 
significantly different at the 5% level.
Significances of differences were confirmed using analysis of variance 
(ANOVA).
6.1.4 Concentration of IgG (total) in serum during pregnancy in allergic 
and non-allergic women
There were no significant differences in the levels of IgG (total) between 
pregnant allergic (9.083 + /-  2.185 g /L ) and pregnant non-allergic women (9.392 
+ / -  1.980 g /L ) and both were similar to the concentrations found in the non­
pregnant women (9.364 + /-  1.797, allergic women; 9.063 +/-1 .566, non-allergic 
women) (Table 13C; Fig. 4). The concentration of IgG (total) remained 
unchanged in both groups during pregnancy, remaining unaffected by the 
period of gestation.
6.1.5 Concentration of total and antigen-specific IgG4 in serum during 
pregnancy in allergic and non-allergic women.
The serum concentration of IgG4 (total) was 224 + /-  43 m g /L  in the 
group of normal non-pregnant women. Significantly higher levels (351 + /  -181, 
p=0.017) were found in non-pregnant allergic women, a finding reported 
previously and thought to be related to the production of 'blocking antibodies". 
In  pregnant non-allergic women, serum levels of IgG4 (total) were significantly 
higher (473 + /-  188, p=0.001) than in the non-pregnant group with no allergic 
symptoms, again, presumably, representing some blocking antibody response,
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Because blood concentrations of IgE (total) have been reported to vary on 
a seasonal basis in response to the pollen count (Borg & Johanson, 1971), 
samples from the non-pregnant women were collected within a one month 
period. However, this was not possible for the pregnant women. Seasonal 
differences were noted (Table 14, Fig.8), although there were no significant 
differences at p=0.05 between any of the four seasons.
The serum concentration of IgE (total) was investigated at three stages 
during pregnancy (see above). The results (Table 15, Fig. 9) indicate a 
progressive fall in IgE concentration in the serum of pregnant allergic women 
as the pregnancy progresses. Six weeks after parturition (Stage C) the 
concentration of IgE (total) was significantly lower than at both Stage A (10 + /-  
3 weeks, p<0.001) and at Stage B (33 + /-  3 weeks, p=0.002). The concentration 
of IgE appeared to return to non-pregnant levels by 6 months post partum, 
although an insufficient number of samples were obtained to test the 
significance of this observation.
No such differences in serum IgE (total) were seen in non-allergic 
pregnant women during pregnancy (Table 12b).
There were no differences in serum IgE (total) in pregnant allergic 
women of different parities (Fig 10).
Antigen-specific IgE was not detected (< 0.35 PR U/m l) in 16 of the 18 
non-pregnant non-allergic women (Table 12d), and only a single serum sample 
from the pregnant non-allergic women had a detectable level of this antibody 
(Table 12b). Measurable levels were found in all of the non-pregnant allergic 
women (mean 17.48 PRU/m l, range 0.65 - 214.3). Significantly lower levels 
were found in the group of pregnant allergic women (mean 1.22 PR U /m l, range 
<0.35 - 27.3, p<0.001). These results are illustrated in Figure 11.
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in this case related to the pregnant state. The group of pregnant allergic women 
had serum levels of IgG4 (total) (396 + /-  219) which were not significantly 
different from either the non-pregnant allergic women or the pregnant non- 
allergic group. These data are illustrated in Figure 5.
Timothy grass allergen-specific IgG4, IgG4 (a-s), was present in the sera 
from women in all of the four groups investigated (Fig 6). Although the highest 
concentration of such antibodies were found in the non-pregnant non-allergic 
women (17.7 per cent) there was no significant difference in the concentrations 
found in any of the groups (Table 13E).
6.1.6 Serum concentrations of total and antigen-specific IgE during
pregnancy in allergic and non-allergic women.
The mean serum concentration of IgE (total) in the group of normal non­
pregnant women was 23.5 kU/1 (range <5 - 63.0). As expected, the mean 
concentration of this immunoglobulin in serum from the allergic group of non­
pregnant women was very much higher than this (mean 200.3 kU/1, range 63- 
834, p<0.001).
In  the group of pregnant non-allergic women the mean serum level of 
IgE (total) was significantly lower (12.6 kU/1, range <5 - 63.1, p=0.012) than in 
the normal non-pregnant group of women. Concentrations of IgE (total) in the 
sera from the pregnant allergic group of women were significantly higher (103.2 
kU/1, range 11 - 700, p<0.001) than in the non-allergic pregnant group. 
Although this is only about half the level found in the non-pregnant allergic 
group, the difference between the two allergic groups (pregnant and non­
pregnant) was not significant (p=0.074).
These results are illustrated in Figure 7.
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6.2 Distribution of Total IgG, Total IgG4 and Allergen-Specific IgG4
Statistical analysis of total IgG and total and antigen-specific IgG4 is 
described in Chapter 6.1 above. Total IgG remained unchanged in both test 
groups during pregnancy and remained unaffected by the period of gestation. 
There was no significant variation in the levels of total IgG between pregnant 
allergic and pregnant non-allergic women and were similar to the non-pregnant 
control groups 3 and 4 (Fig. 4).
Total IgG4 levels were found to be high among non-pregnant allergic 
women when compared with non-pregnant non-allergics. Such antibody levels 
were nearly twice as high in Group 3 non-pregnant allergies when compared 
to Group 4 non-pregnant non-allergics (Fig. 5). During pregnancy, total IgG4 
levels were found to be similar in Group 1 pregnant allergies and Group 2 
pregnant non-allergics and Group 3 non-pregnant allergies. Group 4 non­
pregnant non-allergics showed nearly half the level of such immunoglobulins 
compared with Groups 1, 2, and 3 (Fig. 5). Pregnancy appears to increase the 
levels of such antibodies among pregnant non-allergic women.
Timothy grass allergen-specific IgG4 was present in all four groups, 
Group I  allergic pregnant, Group 2 allergic non-pregnant, Group 3 allergic non­
pregnant women and Group 4 non-pregnant non-allergic women. The highest 
concentration of such antibodies were found among Group 4 non-pregnant non- 
allergic women and were almost twice the level to those of Group I  and Group 
2 (Fig. 6).
Statistical analyses show that the total serum IgG concentration was not 
different in any of the groups of women investigated. There was no significant 
difference in the serum concentration of IgG subclass 4 between pregnant
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allergic women and non-pregnant allergic women. Levels of IgG4 were 
approximately twice as high (p< 0.01) in pregnant women with no allergic 
symptoms than in the non-allergic non-pregnant group. Total IgG4 
concentrations were not different in allergy sufferers and non-allergic women 
during pregnancy; however, among the non-pregnant group of women those 
with allergies had significantly (p = 0.017) higher levels of this IgG subclass than 
those without. Summary of serum concentrations of various immunoglobulins 
in pregnant and non-pregnant women with and without symptoms of allergy 
shown in Table 16.
6.2.1 Distribution of IgE Levels
In both the pregnant and the non-pregnant women there was a higher 
(p<0.001) concentration of total IgE in serum from the allergic than the non- 
allergic subjects. Although the level of IgE was significantly (p=0.004) lower in 
the allergic pregnant group, the differences were relatively small (Table 16) and 
seem unlikely to be of great physiological significance.
In both pregnant and non-pregnant women the serum concentration of 
antigen-specific IgE was higher in the allergic than the non-allergic subjects. 
However, among the allergy sufferers, the concentration of antigen-specific IgE 
was very much lower in the pregnant women, at about 6% of the non-pregnant 
level (p<0.001). The concentration of antigen-specific IgG4 was also lower in the 
pregnant allergy sufferers, being about half of the level found in the non­
pregnant individuals (p<0.002).
The clinical symptoms were determined for this group of allergic women 
during the first trimester of pregnancy. Ten women reported an improvement 
in symptoms during the first trimester, the symptoms became more severe in
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six patients and two reported no change. There was no correlation between 
serum levels of total IgE, allergen-specific IgE or allergen-specific IgG4 and 
symptomatology in these individuals.
Timothy grass pollen is a well known seasonal allergen and the levels of 
IgE, particularly antigen-specific IgE, might be expected to vary w ith the season. 
Analysis of the data from the allergic women during pregnancy failed to show 
any significant differences (at p=0.05) (Fig. 12) in allergen-specific IgE levels in 
three of the four seasons (February-April; May-July; August-October). There 
was only a single pregnancy in which the first trimester fell w ithin the winter 
season (November-January). However, the total serum IgE concentration was 
significantly greater (mean 224 KU/1) in pregnancies during the August-January 
period than in February-July (mean 90 KU/1, p<0.001).
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6.3 Discussion
The present study was undertaken to elucidate the relationship between 
pregnancy and the Type I hypersensitivity immune response among allergic 
women. It has been suggested by Katz (1985) that raised IgE levels are caused 
by T lymphocyte imbalance and polyclonal activation. Pregnancy requires 
modulation of the maternal immune system for the survival of the fetal semi­
allograft. Stites etal., (1979) showed that cellular immunity is depressed during 
pregnancy though conflicting views have been reported regarding the effect of 
pregnancy on humoral immunity. Merritt et al. (1969) found that humoral 
immunity remained unchanged, Ostensen (1983) noted a decrease in serum IgG 
and IgA while IgM  and alloantibodies remained stable. Other observers noted 
a slight increase in immunoglobulin levels during pregnancy (Kenny et al.. 
1977).
In the present study there appeared to be a gradual fall in IgE 
concentration among allergic women during pregnancy (Fig. 9). There is a 
significant fall of allergen specific IgE in this group over the same period (Table 
15). A fall of total IgE following bone marrow transplantation (BMT) was noted 
by Walker et al. (1986) in two patients where there was a "down regulation" of 
total IgE synthesis without loss of allergen specific IgE. This was thought to be 
due to a genetic influence regulated largely by a single autosomal gene R /r  
with the low IgE level allele (R) being dominant over the high level allele (r).
Zetterstrom et al., (1981) used the Phadebas IgE (PRIST) method to 
determine the total IgE in the serum of 412 adult patients w ith respiratory 
symptoms, of which 160 were classified as non-atopics and 252 as having atopic 
diseases. Results showed that total IgE levels below 24 K U /L  were present in
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84% of the non-atopic patients where as 78% of the atopic patients had levels 
greater than 100 K U /L . We were unable to define clearly any such high or low  
responder groups in our study.
It is of interest that during a study of the relevance of m ilk and egg 
specific IgG4 in atopic eczema Shakib (1984) noted total serum IgE levels greater 
than 100 IU /m l in 20 out of 22 eczema patients and 76.9% of those with raised 
specific IgG4 had no demonstrable specific IgE. Borg and Johanson (1971) 
found that, in the pollen season, changes in antigen-specific IgE were more 
pronounced than those of total IgE with rapid increases in levels averaging 
more than 438% of the initial values. A high level of total serum IgE is also 
well documented in parasitic disease.
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7. Clinical Observations
In  the immunoglobulin study a total of 18 pregnant allergic women and 
16 pregnant non-allergic women were enlisted. Clinical details are shown in 
Tables 17 and 18 (Appendix V). We monitored the clinical changes of 18 
allergic pregnant women during pregnancy and the post-natal period. The age 
distribution of the test population in both groups was between 19 and 41 years 
with the average age of both groups being 28.5 years. Nine of the allergies were 
primigravida, four were pregnant for the second time and four had more than 
three pregnancies.
Among the non-allergics five were primigravida, five were pregnant for 
the second time and the rest had more than three pregnancies.
Of the 18 pregnant allergic women, 9 patients had hay fever associated 
with summer wheezing requiring pharmacological intervention in the past. 
Seven or 41 per cent of the group had dual symptoms, e.g. eczema/hay fever 
together and one was known to be a chronic asthmatic with seasonal 
exacerbation of asthma. Among other allergic symptoms two were allergic to 
penicillin and one also reported allergy to nettle.
Tonsil and adenoid problems were reported by 8 patients among the 
allergic group, of which 4 patients had had surgical treatment in the past. We 
also noted a relatively high level of renal glycosuria among the allergies when 
urine tests repeatedly confirmed presence of glucose in 4 patients. Glucose 
tolerance tests failed to confirm diabetes in these women.
High blood pressure was also noted in 4 allergic patients during 
pregnancy.
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Psychiatric problems, e.g. depression and anxiety were present in 4 
patients in allergic group.
One of the interesting observations in the obstetric history revealed that 
4 allergic women or 22.2 per cent of the test population had a previous 
incidence of miscarriage/threatened abortion. W hile such incidence were 
reviewed among non-allergics, only one reported history of two previous 
miscarriages. Non-allergics reported similar levels of tonsillitis/hypertension 
and anxiety related morbidity.
The effect of pregnancy on the clinical symptomatology of the allergy 
remained unclear. Seven of the allergic patients did not notice any significant 
change of symptoms of their pre-existent illness. Four reported worsening of 
symptoms and six improved. These findings are in line with previously 
published data.
7.1 Atopy and Autoimmune Disease in Pregnancy
The observation discussed in Section 7 above, relating to the apparently 
higher prevalence of threatened abortion/miscarriage in the group of pregnant 
women with allergic/atopic symptoms, indicated the need for further 
investigations in both high risk pregnancy w ith immunological disorders and 
normal patients. A  literature review on the subject did not provide any 
previously published useful information on such a relationship. Attempts made 
to analyze computerized obstetrics records both in Sheffield and Buffalo were 
unsuccessful due to inadequacy of recording allergic/atopic disease in obstetric 
clinics. We were, however, able to identify and review the case notes of a 
group of high risk women with a history of repeated abortion. These women
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had history of autoimmune disease/abnormal antibodies with or without active 
immunological disease during pregnancy.
7.1.2 Observation and Management of the Antiphospholipid Syndrome in 
Pregnancy: The Buffalo Experience
The Department of Medicine at The Children's Hospital of Buffalo State
University of New York, Buffalo, USA, has screened approximately 40 patients
since 1986. Almost all these patients were referred by a single obstetric unit of
the hospital and one particular internal medicine group. Preliminary immune
screening confirmed single or multiple immunological abnormalities at the time
of referral to the Medicine Department. Almost all of the women attending the
unit were white and had miscarriage associated immunological disease, were
found to be positive on autoantibody screening without overt symptoms, or
were referred purely for abnormal antibody screening. Case histories of a
group of seven patients are described in Appendix V.
Table 19 shows the clinical summary of SLE patients observed in this
study.
7.2 Observation and Outcome of Pregnancies in Women Attending 
the Langold Health Centre between September 1986 and December 
1990.
We retrospectively reviewed all the pregnancies of women attending the 
ante-natal clinic at Langold Health Centre between September 1986 to December 
1990.
A total of 187 women attended for ante-natal care during the specified 
period. Ante-natal care was shared between the attendant general practitioners 
and hospital obstetricians at Bassetlaw General Hospital, Worksop and 
followed the standard nationally agreed ante-natal care protocol. Review of
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clinical notes and personal interviews (as necessary) based on the allergy 
screening protocol (Form II, Appendix II) confirmed that 104 of these patients 
had no significant history of allergic disease whereas 83 women had confirmed 
allergic symptoms. Table 20, page 117 shows the data from women attending 
the Health Centre.
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Table 2 0.
Data from women attending The Health Centre, Langold, ante-natal clinic from 1986-1990.
Allergic Non-allergic
Number of women 83 104
Conceptions 193 228
Terminations 11 8
Pregnancies analysed 182 208
Threatened miscarriages 4 0(% of pregnancies) (2.2) (0)
Miscarriages 33 11(% of pregnancies) (18.1) (5.0)
Premature delivery 5 1(% of pregnancies) (2.7) (0.4)
Women with 2+ miscarriges 7 1
Women with problem pregnancies 30 10(% of women in group) (36.1) (9.6)
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Details of individual patients included factors, e.g. parity, miscarriages, 
period of gestation, known allergies, blood group and associated medical history 
(Table 21, Appendix V). Nineteen had legal pregnancy terminations. Available 
information confirmed a total 421 pregnancies. Allergic women (83) had 193 
conceptions and non-allergic women (104) had a total of 228 conceptions. 
Among the allergic group, 33 pregnancy losses (18.1%) were reported whereas 
the non-allergic group had 11 pregnancy losses (5.0%) during the observed 
period. Five of the allergic women (6.2%) attended an infertility clinic and 3 
(1.9%) non-allergics attended an infertility clinic during this period. Other 
factors, e.g. blood group, medical history, etc. did not provide any significant 
information relating to high pregnancy loss prevalence among allergic women.
O f the 403 pregnancies considered in the retrospective study, 44 ended in 
first trimester miscarriage, a rate of loss of 10.9%. This is not dissimilar to the 
miscarriage rate found in previously published prospective studies (Regan, et 
al., 1989). Pregnancies of women with symptoms of allergy, had a 3.5-fold 
greater rate of first trimester miscarriage than those of non-allergic women. 
Although this difference could reflect an increase in miscarriages among women 
who have previously miscarried (Regan et al., 1989) both the number of women 
with symptoms of allergy who experienced a miscarriage and the number of 
miscarriages in such women was over 3 times greater than in the non-allergic 
group. Statistical analysis by analysis of the binomial distribution of allergic 
reactions and problem pregnancies showed that allergic women have a 
significantly greater (p < 0.001) chance of having a problem pregnancy than 
non-allergic women.
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among allergic women (p < 0.001). However, there was no difference in rate of 
: conception between the two groups.
These observed differences could be the result of a secondary effect of 
factors such as particular drug use by the allergic patients; however these 
women were specifically advised against continuing drug treatment for their 
allergy as soon as a pregnancy was suspected. Rubin et al.. (1986) reported that 
over 93% of pregnant women avoid exposure to drugs in the first trimester and 
it seems unlikely that the observed difference in miscarriage rate between the 
two groups reported here is drug induced. Although it is possible that there 
might have been other undetected differences in the two groups of patients 
investigated, given the manner in which the sample was selected (all women 
attending an ante-natal clinic over a 52 month period) and the size of the 
sample (187 women, 402 pregnancies) this is unlikely. Furthermore, the data 
from the small group of women suffering from SLE tended to confirm the 
observations from the ante-natal clinical study. Taken overall, the results 
suggest that there may be an underlying abnormality in the allergic women 
predisposing to miscarriage.
7.2.1* Discussion
Little has been published on the immunological responses to allergens 
during pregnancy, studies in this area being confined to late pregnancy relating 
the sensitisation of the fetus in utero to the development of allergy in early 
infancy (Iikura et al.. 1989). One factor that may link allergic symptoms and 
miscarriage could be a defect in the production of antigen-specific
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immunoglobulin IgG4 during early pregnancy in the allergic group. Such a 
breakdown in the production of "blocking" antibodies during pregnancy has 
been linked to recurrent abortion (Mowbray et al., 1984) and may also be 
important in the manifestation of allergic symptoms (Heinen et al., 1984). 
Alternatively, the high levels of histamine released as a mediator of type 1 
hypersensitivity reactions may be an agent in this increased rate of pregnancy 
loss.
In the investigation of the serum concentration of certain 
immunoglobulins in a subgroup of these women (Chapter 6) it was revealed 
that, as expected, IgE levels were around tenfold higher in the allergic than the 
non-allergic pregnant women, the levels being similar in the relevant non­
pregnant control groups. Whereas antigen-specific IgE was also raised in the 
allergic group compared to the non-allergic group during pregnancy, the 
antigen-specific IgE response was very much lower in the pregnant than in the 
non-pregnant allergic group. This suggests that, during the first trimester of 
pregnancy, there may be an inhibition of the antigen-specific IgE response. 
Similarly, although less dramatically, there appears to be an inhibition of the 
allergen-specific IgG4 response during pregnancy.
It is tempting to postulate an immunological basis for the observed 
increase in the rate of early miscarriage in the pregnant allergic women and to 
relate this to the immunoglobulin findings. One factor could be the apparent 
block in the production of antigen-specific immunoglobulins (IgG4 and IgE) 
during early pregnancy in this group. This may reflect a breakdown in the 
production of ’blocking" antibodies during pregnancy, a deficiency of which is 
linked to recurrent abortion (Mowbray, et al.. 1984). Although it has been
120
proposed recently that IgE is important in antigen capture and presentation 
(Mudde etal., 1990) the role of this immunoglobulin has not been investigated 
in pregnancy. An additional factor involved in the higher rate of pregnancy 
loss in the pregnant allergic group of women could be a general stimulation of 
the maternal immune system consequent upon the high level of IgE in these 
individuals. This could result in an increase in the production of a range of 
cytokines including IL-2 which has been shown to prevent fetal development 
in mice if administered after mating (Tazabwala, et al.. 1989).
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8. Final Discussion and Concluding Remarks
The immunology of human pregnancy has been investigated widely, 
particularly relating to the survival of the semi-allogeneic feto-placental unit in 
the potentially hostile immunological environment of the female reproductive 
tract. This survival has been related to a number of factors including the 
secretion of blocking antibodies (of the IgG4 subclass) by the maternal immune 
system (Rocklin, et al.. 1979), presumably directed against paternal antigens of 
the fetus, and the production of localised immunosuppressive molecules such 
as the protein Placental Protein 14 (Bolton, et al., 1987). A defect in any of these 
could result in threatened miscarriage, actual miscarriage or, if manifested later 
in gestation, possibly as premature delivery. Indeed, a deficiency of blocking 
antibodies has been associated with recurrent spontaneous abortion, leading to 
immunisation with paternal cells as a treatment for this condition (Mowbray, 
et al.. 1984).
Despite extensive studies on the maternal immune system, little is known 
of the role of IgE during pregnancy. Investigations carried out in this area have 
concentrated on late pregnancy in the context of intrauterine sensitisation and 
the development of allergy during early infancy (Iikura et al., 1989).
8.1 The Immunoglobulins
The serum levels of IgG, total IgE, total IgG4, allergen specific IgE and 
allergen specific IgG4 were measured in non-allergic and allergic pregnant 
women during early and late pregnancy and the post partum period. These 
levels were compared with non-pregnant controls. All allergic women had a 
demonstrated allergy to Timothy grass pollen.
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8.1.1 IgG and the Sub-Classes
The levels of total IgG remained unchanged during pregnancy and there 
was no significant difference noted among test groups. Total IgG4 increased 
significantly during pregnancy among non-allergic women. Allergic women 
demonstrated a higher level of total IgG4 in both the pregnant and non­
pregnant states.
The level of total IgG in the present study remained unchanged during 
pregnancy, a finding that differed from some previously published reports, e.g. 
Gudson et al. (1969) Amino et al. (1978). However, these findings are in 
agreement with those of M iller et al. (1984), Ostensen and Merritt et al. (1969), 
and Kenny et al. (1976) where no significant changes of IgG were noted.
A high level of IgG4 (total) was noted in both allergic and non-allergic 
women during pregnancy. Such an observation is of interest as IgG4 is thought 
to be a 'blocking' antibody both during pregnancy and also in allergic diseases.
The role of allergen-specific IgG4 in the present study is unclear. A ll four 
test groups demonstrated the presence of this sub-class of antibody in their sera 
with the highest concentration among non-pregnant, non-allergic women. These 
data suggest that in allergic women the high levels of IgG4 are not further 
increased during pregnancy. Such an observation indicates that IgG4 secretion 
by these women may have already reached maximal levels.
Another interesting clinical observation in the present study is that 
allergic women appear to have a higher tendency to miscarry when compared 
with non-allergic women. Whether such a finding can be attributed to "failure" 
of the IgG4 antibody production to enhance the existing IgG4 antibody 
repertoire due to increasing demand caused by pregnancy is not known.
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Among the non-allergic women IgG4 levels were increased during pregnancy. 
It is possible that such newly synthesised antibodies have a 'blocking” role 
during pregnancy and thereby contributed to a relatively lower incidence of 
miscarriage among these women. Rocklin et al. (1979) claimed that maternal 
blocking antibodies are absent from the serum of spontaneous aborters.
In Group 3 (non-pregnant allergic women) a significantly higher level of 
IgG4 and IgE was noted when compared with Group 4 non-pregnant non- 
allergic patients. Such findings conform with the currently held views which 
suggest that chronic antigenic exposure produces a predominant IgG4 response. 
The phenomenon is likely to be the result of a sequential "down-stream" switch 
of genes along the CH gene locus (Shakib, 1988). Class switching from IgM  to 
IgE is also postulated among atopic individuals.
The findings reported here may suggest that such allergen specific Ig4 
antibodies are part of a normal general immune response and may have a 
blocking role among non-allergics against local environmental factors. These 
findings are contradictory to the previously reported survey where inhalant 
antigen-specific IgG4 was rarely detectable in 156 normal individuals taking part 
in a community survey (Merrett, 1983). These contradictory findings are 
probably due to environmental factors, as the study population in this project 
is from a rural area with extensive grasslands and an abundance of airborne 
pollen (Appendix I).
8.1.2 IgE and Allergen-Specific IgE
The results showed that total IgE decreased during pregnancy and that 
the decrease is greater as pregnancy advances. Allergen-specific IgE 
demonstrated a highly significant decrease in pregnancy among pregnant
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allergic women but remained the same as pregnancy proceeded. No such 
antibodies were found among non-pregnant non-allergic women and pregnant 
non-allergic women.
Previous reports on the level of IgE during pregnancy is controversial. 
The continuous variability of serum IgE level concentrations in health and the 
allergic state has been well documented. So far four studies have been reported 
in the literature relating to the changes in serum IgE levels during pregnancy. 
Knoblock etal. (1974) reported no statistical difference between serum IgE levels 
in different subjects during the first trimester of pregnancy compared with the 
levels in the third trimester. Amino et al. (1978) serially measured serum IgE 
levels during early, mid- and late pregnancy in the normal pregnant women 
and found no significant change in mean levels and no consistent trend towards 
increasing or decreasing levels. Gluck and Gluck (1976) studied the serum IgE 
during pregnancy in 17 women with asthma and six controls. They reported 
that those with an increased or unchanged IgE had a tendency for their asthma 
to worsen during pregnancy, whereas decreasing levels of IgE were seen in 
normal controls and in asthmatic women whose asthma improved or remained 
unchanged during pregnancy. In contrast, Schatz et al. (1985) were unable to 
find any difference in serum IgE levels during early, m id- and late pregnancy 
or post partum in 18 women whose asthma had improved during pregnancy 
compared with 16 women whose asthma had worsened. No significant 
relationship was observed between the IgE levels and symptomatology during 
pregnancy among the allergic group in this study.
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8.1.3 Mast cell mediators
Products of arachidonic acid metabolism which are implicated in IgE- 
dependent inflammation and are newly generated by mast cells via the 
cyclooxygenase and lypoxygenase pathways, such as prostaglandin E, 
prostacyclin and thromboxane A2, are increased during pregnancy. In  contrast, 
levels of the pre-formed mediator histamine decrease.
Observations suggest that prostaglandins are necessary for pregnancy to 
continue. Reports published on animal studies (Lewis et al. 1982, Hyland et al. 
1982, Hwang et al. 1988, Watson et al. 1989) indicate that fetal and maternal 
prostaglandins are important in pregnancy maintenance. Prostaglandins are 
known to regulate T-cell lymphoproliferative responses by modulating the 
development of receptors for transferrin (Chaouat et al., 1985). In humans, the 
use of drugs such as prostaglandin inhibitors during pregnancy is 
contraindicated (British National Formulary 1990). Aspirin in high dose was 
reported to cause congenital malformation, perinatal mortality and low birth 
weight, whereas low doses of aspirin given to selected groups of pregnant 
women with associated alloimmune diseases are beneficial for both mother and 
the baby. Imbalance between thromboxane and prostacyclin is reported during 
pre-eclampsia and related complications (Walsh, 1990). Prostaglandin release 
can be pharmacologically modulated by aspirin and indomethacin by inhibiting 
the cyclooxygenase pathway in a time-dependent, concentration-dependent 
manner (Smith and Lands, 1971).
In  the present study, attempts have been made to determine the nature 
and effect of pregnancy on inflammation induced by natural allergens such as 
grass pollen. It is known that serum factors in pregnancy can markedly
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decrease lymphocyte proliferation to antigen and mitogen in vitro, although the 
physiological significance of these observations is not well-established. All 
biological studies by their very nature, have a high degree of variability. The 
present study is influenced by additional factors: (1) stability of serum Ig levels; 
(2) admixture of maternal blood with fetal blood; (3) genetic regulation of total 
and allergen-specific immunoglobulins; (4) endocrine events that are controlled 
by both maternal and embryonal mechanism at different stages of pregnancy; 
(5) problems of reproducibility in the laboratory environment and finally, (6) the 
effect of environmental factors such as pollen count and seasonal variation. In  
spite of such difficulties the results showed that the levels of total and allergen 
specific IgE decrease in both allergic and non-allergic women as pregnancy 
advances. The levels of these immunoglobulins in early pregnancy were higher 
than in later pregnancy suggesting that late pregnancy factors could play a 
significant role in suppressing the production of such immunoglobulins.
Evaluation of disease activities assessed from parameters made on the 
basis of clinical assessment and personal questionnaire did not confirm a 
uniform relationship between serum immunoglobulin levels and clinical 
symptomatology.
8.2 Hypersensitivity Reactions and the Fetal Semi-Allograft
In  the introductory Chapters IgE mediated inflammatory events resulting 
in infiltration of leucocytes, eosinophils, neutrophils and aiso the generation of 
substantial amounts of LTB4 and PAF acether were discussed. These mediators 
promote adherence of eosinophils and neutrophils to endothelial cells of post- 
capillary venules. Late phase IgE mediated events result in oedema, exudation
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of proteins and hypersecretion of other inflammatory products. Extensive 
epithelial denudation and eosinophil infiltration is noted during such events.
In  the human reproduction process, destruction of maternal epithelium 
following implantation of the fertilized egg is noted and is thought to be 
trophoblast initiated. Trophoblast, exhibiting foreign paternal antigens may be 
regarded as a semi-foreign allograft and is likely to initiate a classical graft 
rejection reaction.
In  the graft rejection process, foreign M HC. Class II  antigens on the graft 
stimulate host T-helper cells (Th) and cytotoxic T-cells (Tcyt) to destroy the 
target graft cell. Tcyt cells recognise the graft cell via the foreign M H C  class 1 
antigen. The cells reacting to the graft release lymphokines which stimulate 
macrophages to enter the graft and destroy it. Although, in pregnancy, M HC  
antigens are absent (or perhaps expressed at extremely low density) on 
trophoblast tissues of the fetal semi-allograft in direct contact w ith maternal 
blood (Billington and Bell, 1983 a,b), other major trophoblast populations 
opposing maternal decidual tissue have been shown to express Class I  M H C  
antigens. Paternally encoded Class 1 M HC antigens have been described on the 
spongy zone trophoblast layer of the placenta in the rat. M HC Class I I  (H LA - 
DR) positive cells found in human placenta are thought to be macrophages 
(Sutton et al.. 1983). Starkey (1987) reported that cytotrophoblast cells can bind 
antibody specific for M HC Class II HLA-DP antigen. TLX (trophoblast 
lymphocyte cross reactive) antigens are also reported in early pregnancy (Faulk 
and McIntyre, 1983).
Delayed hypersensitivity reactions are implicated in graft rejection 
mechanisms. An initial IgE mediated immediate hypersensitivity reaction
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followed by a late phase delayed hyersensitivity reaction after challenge by 
antigens of the fetal semi-allograft could possibly occur at about 4 days 
following fertilisation, coinciding with the arrival of the morula at the uterus 
through the tubal isthmus. Such a hypothesis is compatible with our present 
state of knowledge. The proposed mechanisms for graft rejection are, therefore, 
possibly applicable in the context of pregnancy. A vigorous IgE-mediated 
delayed hypersensitivity reaction may result in an immune reaction resulting 
in fetal expulsion in a similar manner to graft rejection. While 
alternative/associated immunosuppressive mechanisms of pregnancy are 
already geared to counteract such a rejection reaction, in a genetically pre­
disposed select group of women such as atopies, such events may contribute to 
an increased risk of spontaneous abortion.
Atopic individuals are known to mount an immune response to 
environmental antigens with excessive production of IgE due to T-cell 
abnormalities. It is, therefore, possible that these women have an inherent, 
inbuilt tendency for a vigorous IgE mediated, delayed hypersensitivity 
(IL 4/C D 23/Ig E R ll dependent) reaction during pregnancy, thus increasing the 
prevalence of threatened abortion. In  a normal healthy pregnancy initial 
membrane disturbances involved in implantation may be initiated by IgE 
mediated events. Failure to mount such a reaction or sensitisation phase may 
inhibit or impair further pregnancy processes and thereby cause infertility in 
some women. On the other hand, inadequate, late phase (challenge phase) 
events, such as a distorted release mechanism of secondary inflammatory 
mediators may result in spontaneous abortion (50% of in vivo fertilised human
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eggs are aborted with a substantial proportion being due to lethal genes and 
chromosome anomalies (Clark et al., 1986a).
The enhanced effector functions of IgE antibodies are well documented 
in live targets, e.g. in helminthic diseases, whereas microbial or tumoral targets 
do not evoke IgE responses. The late appearance of IgE in phylogeny as well 
as the high rate of evolution of the E chain in comparison w ith other 
immunoglobulin heavy chains (Ishida et al., 1985) suggest that nature has 
selected for the continuous existence of this class of antibodies. There is 
therefore the possibility that IgE is an essential participant in the complex 
immune responses in pregnancy as well as parasitic infections and other 
clinically significant allergic responses to environmental antigens.
It has been shown that IL4 stimulates and IFNgamma inhibits 
lipopolysaccharide (LPS) activated murine B cells to secrete IgE and IgG l in 
vitro. IL4 produced by T cells appears to determine whether IgM  production 
switches to either IgE or IgG. The stimulatory role of IL4 is of particular 
interest in allergy as the over-production of IgE antibodies is the major cause 
of allergic diseases. Delespesse et al., (1989) reported that IL4 is the ,rbinding- 
factor" in enhancing IgE synthesis.
Finkleman et al., (1986) investigated the T-help requirement for the 
generation of an in vivo IgE response in mice and reported that the IgE 
response is blocked by anti IL4 antibody. However, such an effect appeared to 
be short-lasting.
8.3 Miscarriage, Allergy and Effects on Seasonality of Human Birth
Miscarriage is defined as "the expulsion of a fetus from the womb before 
28 weeks of pregnancy". It is now estimated that up to 50 per cent of in vivo
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fertilized human eggs are aborted (Clark et al., 1986a). The causes of such 
pregnancy loss are varied and various physiological and social factors are 
attributed by the medical profession and by the public at large. These include: 
(1) abnormal fetus; (2) associated illness; (3) hormonal imbalance; (4) age; and 
(5) psychological factors. Seasonal variation in the human birth rate is an 
interesting and yet unresolved area. It is, however, well documented that the 
pattern of birth shows a major peak in spring and a minor peak in autumn 
(fames, 1990). There is substantial literature on the seasonality of human births 
(Cowgill, 1966a, 1966b). Although attempts have been made by the social 
scientists to explain such a variation, no satisfactory explanation is yet available. 
Paraskevaides et al. (1988) studied the seasonal distribution in conceptions 
achieved by artificial insemination by donor. This study of 259 conceptions at 
an artificial insemination clinic confirmed that conception is influenced by the 
season of the year. Conception was not influenced by the number of donors or 
patients attending the clinic, the frequency of inseminations, or medical skill. 
Conception was found to be more common from early winter until early spring 
(October to March) with a peak in November. Variables such as frequency of 
intercourse and ovulation were excluded in these women.
Such a finding may suggest that seasonal variation may affect the quality 
of the ovulated egg or the maternal receptibility to the fertilized egg. In  this 
group of pre-selected patients other known contributory factors, such as 
chromosomal or hormonal impairment, were excluded and the pattern and 
distribution of conception was found to be similar to natural conception. Such 
a finding is of interest in the context of the seasonal distribution of pollen count 
(it is well documented, that the pollen count is highest from April to August)
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and is inversely proportional to the rate of conception. Such an observation 
may suggest that during the pollen season, the immune system is stimulated by 
natural allergens to that of increased "alertness" whereby any "foreign" antigen 
is likely to precipitate a hostile reaction. As an invading sperm or a fertilized 
ovum may produce a similar immune response (the pregnant mother is 
competent to respond immunologically to the fetus with the production of an 
immunological reaction against the conceptus) the degree of such a reaction is 
of vital importance. An exaggerated or inappropriate adaptive host response 
(defined as a hypersensitivity reaction) is likely to cause tissue damage both to 
invading sperm and also to the host endometrium during such an "altered" 
immune state.
As immunoglobulins of various types are responsible for the expression 
of antibody-antigen immune response in such types of reactions and subsequent 
inflammatory processes, involvement of IgE antibodies at the earliest stage of 
pregnancy processes makes it a possible hypothesis. However, as the 
immunoglobulins of various types do not function in isolation, other types of 
immunoglobulin are also likely to play respective roles in such a phenomenon. 
IgG antibodies are probably of critical importance in such a situation whereby 
the "blocking effect" of such antibodies w ill affect the ultimate fate of the 
invading sperm or the immune response generated by the fertilized ovum. In  
this study an increased prevalence of miscarriage among the allergic women 
was observed. Pollen induced saturation of IgG4 antibody production in these 
women, with a subsequent failure to secrete pregnancy associated IgG4, 
presumably directed against paternal antigens may increase the chances of a 
'blighted fertilized egg" or hostile endometrium, and could result in an
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increased number of miscarriages. A quantitatively greater response could lead 
to effects earlier in the pregnancy and manifest as reduced fertility. 
Theresulting rate of conception during the pollen season may be responsible for 
the observed seasonal variation of human births. If  the findings reported here 
can be repeated elsewhere there could be significant implications for the 
management of the allergic woman who is or wishes to become pregnant. It 
would be of great interest to determine whether approaches such as 
desensitisation to specific allergens or the use of peptide vaccines (Stanworth et 
al., 1990) might overcome the problems described here.
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APPENDIX I
ENVIRONM ENTAL FACTORS
1. Pollen count from 31 May to July 1984
21 May to August 1985 
30 May to 27 July 1986
2. Distribution of local agricultural products.
3. Distribution of local forestry.
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ROTHERHAM METROPOLITAN BOROUGH COUNCIL 
DEPARTMENT OF ENVIRONMENTAL HEALTH
POLLEN COUNT FOR 1954
Date Pollen Count Date Pollen (
.May 31st 103 July 13th 8
June 1st 176 '• 14th • 29
2nd 7 15th ' 31
3rd 36 16th 33
ath 35 17th 72
Sth 22 18th 64
6th 3 19 th 14
7th 8 20 th 23
8 th 34 21st 136
9 th 34 22nd 20
10 th - 23rd 97
11th - 24 th 43
12th 31 25th 13
13th 58 25th 17
14 th 48 27th 9
15 th 222 26 th 3
16th 161 • 29th 25
17th 195 30th 17
18 th 301 31st 24
19th 182
20 th 156
21st 168
22nd 58
23rd * 59
24 th 25
25th 220
26th 174
27th 230
26th 146
29th . 63
30th 34 ,
July 1st 162
2nd 89
3rd 65
4 th 252
5 th 337
6th 143
7 th 353
8th 263
9th 173
10 th 102
11th 116
12th 54
1 6 4
ROTHERHAM METROPOLITAN 30RQUGH COUNCIL
Hay
20th 
21st 
22nd 
23rd 
24 th 
25th 
26th
27 th
28 th
29 th 
30th 
31st
f ~^une
1st
2nd
3rd
4th
5th
6 th
7th
8th
9th
10th
11th
12th
13th
l<»th
15th
16th
17th
18th
( 19th
20th 
21st 
22nd 
23rd 
24th 
25th
26 th
27 th
28 th 
29th
30 th
POLLEN COUNTS 1985 
July
1st 190
2nd 310
3rd 386
4th 251
5th 175
6th 148
7th 217
8 th 191
9th 114
10th 174
11th 123
12th 113
13th 242
14th 88
15th 60
16th 34
17 th 52
13th 39
19th 34
20th 33
21st 30
22nd . 23
23rd 176
24th 83
25th 80
26th 28
27th 42
28th 7
29th 3
30th 25
31st 10
August
1st 8
2nd 24
3rd 4
4th 0
5th 3
6th 0
7th 7
8th 31
2
3
4
13
38
57
No count
No count
19
31
33
20
47
38
26
25
S1
2
1011
19
8
13
111120
45 •
34
55
78
138
48
35
190
154
113
87
40
133
334
134
1 6 5
ROTHERHAM METROPOLITAN BOROUGH COUNCIL
DEPARTMENT OF ENVIRONMENTAL HEALTH
POLLEN COUNT FOR 1986
May July
30th 14 1st 98
31st 10 2nd 204
3rd 132
June ' .* 4th 36
Sth 20
1st 23 6th 45
2nd 24 7th 69
3rd 23 8th 105
4th 17 9th 88
Sth 6 10th 32
Sth 11 11th 52
7th 16 12th 6
Sth 20 13th 31
9th 16 14th 99
10th 4 15th 130
11th 15 16th 93
12th 20 17th _ 24
13th 13 18th ' 9
14th 14 19th 24
15th 28 20th 7
16th 58 21st 17
17th 23 22nd 8
18th 24 23rd 8
19th 53 24th 16
20th 11 25th 1
21st 36 . 26lh 22
22nd 18 27th 15
23rd 8
24th 91
25th 126
25th 102
27 th 79
28th 97
29th 76
30th 44
ll*
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ADAS'
Ministry of Agriculture, Fisheries and Food 
Copthall House Potter Street Worksop Notts S80 2ER
Telex T e le p ho n e  W oricsop 4 75 2 S 3  e x t
Y o u r  re fe re n c eD r  B a r u a
L a n g o l d  H e a l t h  C e n t r e  O ur re fe re n c e
D o n c a s t e r  R o a d  C L F / J M
L a n g o l d  D ate
W o r k s ° P  2 5  S e p t e m b e r  1 9 8 6N o t t s
D e a r  D r  B a r u a
I  a m  w r i t i n g  i n  r e s p o n s e  t o  y o u r  r e q u e s t  f o r  i n f o r m a t i o n  t o  h e l p  y o u  i n  a  s t u d y  
o f  h a y  f e v e r  d u r i n g  h a r v e s t .
C R O P S  GROW N I N  T H I S  A R E A
T a b l e s  1 a n d  2  s h o w  t h e  a r e a  o f  v a r i o u s  c r o p s  i n  N o t t i n g h a m s h i r e  a n d  i n  t h e  p a r i s h e s  
a r o u n d  L a n g o l d .  T h e  d a t a  i s  t a k e n  f r o m  t h e  J u n e  1 9 8 4  c e n s u s  a n d  i s  t h e  m o s t  r e c e n t  
a v a i l a b l e .
T h e  c r o p p i n g  i n  p a r t i c u l a r  a r e a s  o f  t h e  c o u n t y  d e p e n d s  l a r g e l y  o n  t h e  s o i l  t y p e .  
S a n d l a n d : -  P o t a t o e s ,  s u g a r  b e e t ,  b a r l e y ,  p e a s  ( a n d  s o m e  w h e a t ) .
L i m e s t o n e : -  W h e a t ,  b a r l e y ,  o i l s e e d  r a p e ,  p o t a t o e s .
K e u p e r  M a r l  ( i n  t h e  e a s t ) : -  W h e a t ,  b a r l e y ,  o i l s e e d  r a p e  ( a n d  s o m e  b e a n s ) .
T R E N D S  I N  C R O P P IN G
C r o p p i n g  t r e n d s  a r e  s h o w n  i n  t a b l e  3 .  I n  a d d i t i o n  i t  i s  i n t e r e s t i n g  t o  n o t e  t h a t  
t h e  a c r e a g e  o f  g r a s s l a n d  h a s  d e c l i n e d  n o t i c a b l y .
C O N S E R V A T IO N
A s  i s  t y p i c a l  o f  m o s t  o f  t h e  U K ,  t h e r e  h a s  b e e n  a  d e c l i n e  i n  t h e  a c r e a g e  o f  h a y  c u t  
e a c h  y e a r .  T h i s  i s  d u e  t o : -
1 .  A  r e d u c t i o n  i n  l i v e s t o c k  n u m b e r s .
2 .  A n  i n c r e a s e  i n  s i l a g e  m a k i n g .
I n  a d d i t i o n  i t  m a y  b e  i n t e r e s t i n g  t o  n o t e  a n  i n c r e a s e  i n  t h e  u s e  o f  s t r a w  c h o p p e r s
( e i t h e r  m o u n t e d  a t  t h e  b a c k  o f  t h e  c o m b i n e  o r  a s  a  s e p a r a t e  m a c h i n e )  o v e r  t h e  p a s t  
2 - 3  y e a r s .  T h e s e  c h o p  t h e  s t r a w  t o  a p p r o x i m a t e l y  3  -  4 "  s o  t h a t  i t  c a n  b e  e a s i l y  
i n c o r p o r a t e d  i n t o  t h e  s o i l ,  e i t h e r  a s  a n  a l t e r n a t i v e  t o  b u r n i n g  o r  t o  f a c i l i t a t e  
b u r n i n g .
A R A B L E  W E E D S
C o m m o n  a r a b l e  w e e d s  i n  t h e  a r e a  a r e  a s  f o l l o w s : -
G r a s s e s :  S t e r i l e  B r o m e  )
B l a c k g r a s s  )  i n c r e a s i n g  w i t h  i n t e n s i v e  a r a b l e  c r o p p i n g
W i l d  o a t s
C o u c h
A n n u a l  m e a d o w  g r a s s
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TABLE \
A R E A  O F  A R A B L E  C R O P P IN G  I N  N O T T IN G H A M S H IR E  ( J U N E  1 9 8 4  C E N S U S )  
D a t a  f o r  a l l  o f  N o t t i n g h a m s h i r e  ( h a )
T o t a l  a r e a  1 5 3 8 9 9
C r o p s  a n d  f a l l o w  1 1 3 4 7 7
G r a s s l a n d  8 5 3 2 5
R o u g h  g r a z i n g  1 2 0 3
W o o d l a n d  1 6 9 8
O t h e r  l a n d  2 1 9 5
C r o p s  a n d  F a l l o w
W h e a t  4 4 9 8 0
W i n t e r  b a r l e y  2 6 1 1 4
S p r i n g  b a r l e y  1 1 2 0 4
O a t s  7 9 4
M i x e e  c o r n  2 7
R y e  1 5 4
M a i z e  9 1
P o t a t o e s  5 2 3 2
S u g a r  b e e t  c 8 1 9 4
C r o p s  f o r  s t o c k f e e d : -  
B e a n s  4 4 0
T u r n i p s / s w e d e s  8 5
F o d d e r  b e e t / m a n g e l s ,  k a l e  3 2 3
O i l s e e d  r a p e  1 2 1 9 5
O t h e r  c r o p s  7 4
F a l l o w  4 0 4
H o r t i c u l t u r e  2 4 3 7
1 6 9
TABLE a
ARABLE C R O P P H E  I N  S P E C IF IE D  PAR ISH ES -  N  NOTTINGHAM SHIRE (J U J E  1 9 8 4 )  
( h a )
S t y r r u p /
O l d c o t e s B l y t h H o d s o c k C a r l t o n W o r k s o p B a r n b y  ]
T o t a l  a r e a 7 4 2 1 1 6 3 * 9 6 4 1 0 6 5 3 6 7 1 4 5 7
C r o p s  a n d  f a l l o w 6 7 8 8 6 2 8 1 0 8 6 8 2 7 2 6 3 9 3
G r a s s l a n d 5 2 2 7 0 1 2 8 1 5 9 8 2 7 1 1
R o u g h  g r a z i n g 1 0 5 3 4 0
W o o d l a n d 9 1 9 5 1 9 . 3 1 9 4
O t h e r 3 1 2 2 1 9 4 5 9
C r o p s  &  F a l l o w : -
W h e a t 2 2 6 1 9 4 1 9 7 2 6 8 5 9 4 5 6
W i n t e r  b a r l e y 8 5 1 4 9 1 9 1 2 1 4 5 6 8 1 2 2
S p r i n g  b a r l e y 1 1 2 2 1 5 1 6 8 1 6 9 4 7 8 8 9
O a t s 5 6 0
M i x e d  c o r n -
R y e -
M a i z e -
P o t a t o e s 6 7 , 6 8 1 4 1 3 7 2 8 7 3 0
S u g a r  b e e t 5 4 1 0 3 1 7 5 1 2 4 2 5 9 9 1
C r o p s  f o r  s t o c k f e e d : -  v
B e a n s 1 5 1 7
T u r n i p s / s w e d e s 2 2
F o d d e r  b e e t / t n a n g e l s  e t c 1 6 7
O i l s e e d  r a p e 1 8 6 3 3 0 5 0 2 6 0
O t h e r  c r o p s -
F a l l o w 0 . 4 2 2 2 8
H o r t i c u l t u r e 9 9 5 .7 1 4 1
1-7-0
TABLE 3
TRENDS IN ARABLE
Wheat 
Barley 
Potatoes 
Sugar beet 
Oilseed rape
CROPPING (NOTTINGHAMSHIRE) 1980 - 85 (ha)
1980 1984 1985
32.000 45,000 45,000
46.000 37,000 37,000
4,700 5,200 5,000
9.000 8,000 8,000
5.000 12,100 12,300
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The Forest District Office
FORESTRY COMMISSION
Edwinstowe Mansfield Notts NG21 9JL
Tdaphon* M «nj(l« ld (0623) 822447
Your re fs rtn c j
D r  B a r n a
L a n g o l d  H e a l t h  C e n t r e  
D o n c a s t e r  R o a d  
L a n g o l d
Our reference S F 1 7 / 2
0 , , » 3 0  S e p t e m b e r  1 9 8 6H r  W o r k s o p
N n t t a - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
D e a r  D r  B a r n a
I  r e f e r  t o  o u r  r e c e n t  t e l e p h o n e  c o n v e r s a t i o n  w h e n  I  p r o m i s e d  y o u  i n f o r m a t i o n  
o n  t h e  r e l a t i v e  a b u n d a n c e  o f  b r o a d l e a f  t r e e  s p e c i e s  i n  t h e  v i c i n i t y  o f  W o r k s o p .
I  h a v e  l o o k e d  u p  t h e  r e c e n t  c e n s u s  o f  t r e e s ^ i n  N o t t i n g h a m s h i r e  a n d  a b s t r a c t e d  
t h e  f o l l o w i n g  i n f o r m a t i o n .  O b v i o u s l y  t h i ^ ’ i o e s  n o t  r e f e r  t o  t h e  W o r k s o p  a r e a  
s p e c i f i c a l l y  b u t  t h e  d a t a  i s  n o t  b r o k e ’ T v ^ p v n  o n  a  s u b - c o u n t y  b a s i s : -
I  t r u s t  t h a t  t h i s  i i . i o r m a t i o n  i s  o f  u s e t ^ ^ o u .
Y o u r s  s i n c e r e l y
D  A  C
F o r e s t  D i s t r i c t  M a n a g e r
1 7 2 V -
Species Areas of Woodland (hectares)
Birch
Sycamore
O a k
Beech
Ash
Sweet Chestnut.
Poplar
Elm
O t h e r  b r o a d l e a v e s  
Mixed M
1 3 ^9
'1??3
1178
600
S89
393
(probably less now)
139
895
1 7 3
APPENDIX II
CL IN ICAL DATA RECORD FORMS
1. Form I. Copy of case history form used in the preliminary study.
2. Form II. Copy of ante-natal history form.
3. Form HI. Copy of skin test reaction record card.
4. Form IV . Daily Symptom Record Card.
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F O R M  I
Asthma/Atopic Disease 
Record Chart
S urnam e........................................................................ Forenames
(BLOCK LETTERS)
Date of Birth __________ __ ______ ________________ ___________
Address...............................................................................................
S e x ..................................................................................Occupation
Name of G.P........................... :......................................
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i
Bom in the U.K. YES/NO
If the answer to the above question is NO, please answer the follow ing:
Place of birth ...............................................................................................
Age at coming to the U.K............................................................................
Number o f years in the U.K........................................................................
Do you/your child suffer from :
Yes No Not sure
Wheezing/Chronic Cough □ □ □
Wheezing/Nocturnal Cough □ □ □
Wheezing/Cough after exercise □ □ □
Asthma □ □ □
Hay Fever □ □ □
Perennial Rhinitis □ □ □
Sneezing □ □ □
Eczema □ □ □
Others, e.g. nasal polyp., urticaria
Age o f onset o f sym p tom s.........................................
Severity o f symptoms M ild 0  Moderate 0  Severe f~1
Are symptoms All year round 0  Seasonal 0
If seasonal:
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Perennial 
Affected by
Constant 0  
Wet □  
Summer 0
Animal Contacts:
Cat 0  Dog 0  Gerbil 0  
Rabbit 0  Horse 0
House Dust 0  Grass Pollen 0
Intermittent 0  
Dry Q  Hot 0  Cold 0
W inter 0  Indoor 0  O utdoor 0
Hamster etc. 0  Budgies and cage birds I I
Cow 0  Sheep 0  Poultry 0
O th er.................................................................................
176
Does anyone smoke in the house?................................................................
If YES 1. How many per day ................................................................
2. How long have you sm oked ............................................
Information relating to  early feeding:
Was the child bottle fed? YES Q  NO Q  .
Breastfed? YES Q  NO Q ] If YES, to  what age?
History of allergy to:
YES NO
Egg □ □
Wheat □ □
Milk □ □
Otherfood 
products 
e.g. prawns □ □
Any plants 
or flowers □ □
Family History
Asthma Hay Fever Allergy
Father □ □ □
Mother □ □ □
Brother/Sister Age Sex
1 ) □ □ □ □ □
2 ) □ □ □ □ □
3) □ □ □ □ □
4) □ □ □ □ □
5) □ □ □ □ □
Are y o u  a vegetarian? YES f~~l N O  □
Is there any significant dietary difference YES Q  NO I I
Present m edication.............................................................................................
Do you think your present treatment is satisfactory? YES Q j NO f~ l
P.E.F.R. (P.E.F.R. to be recorded three times at four m onthly intervals, should include early May)
Please record the best o f three readings on each occassion
Date Morning Afternoon N ight
1st--------------------------------------------------- ------------------  -------------------  -------------------
k.2nd ___________  ___________  ___________
3rd ------------------  -------------------  -------------------
1 7 7
Plan of action:
Initia l Assessment and Comment: Recorded by
Intermediate Assessment and com ment: Recorded by
Final Assessment and Comment: Recorded by
NOTE:
Diagnostic criteria o f severity of symptoms.
Mild - m inor symptoms and signs suffered to warrant treatment, but 
insufficient to greatly alter daily life style.
Moderate - more marked symptoms and signs sufficient to alter life style, 
e.g. confined to  home, time o ff school/work.
Severe - marked symptoms and signs requiring frequent medical care, 
sufficient to  alter normal life style and activities.
178
i
FORM II
ANTE-NATAL ALLERGY/ATOPY RECORD CHART
CONSULTANT:
SURNAME: FORENAMES:
DATE OF BIRTH: CAUCASIAN
ASIAN
AFRO-CARIBBEAN I INAME OF GENERAL PRACTITIONER
DO YOU SUFFER FROM ASTHMA ECZEMA HAY FEVER ALLERGY
If yes: Age of onset ____
Severity of Symptom: Mild (1) Moderate (2) Severe (3)
Are Symptoms All year round j [ Seasonal ] I
If SEASONAL - PLEASE INDICATE:
I Jan I Feb I Mar I Apr ! May ! Jun I Jul ! Aug I Sep i Oct I Nov I Deo I •I I I I I i I I I I I I I
PLEASE RECORD:
SINCE PREGNANCY - SYMPTOMS Less I___[ Increased I I No change I I
PLEASE INDICATE - Months when symptoms present since pregnancy
I Jan I Feb I Mar L Apr I May I Jun I Jul I Aug I Sep I Oct I Nov I Dec I Period of
I I I I i I I I I I I I I Pregnancy
(in months)
Severity of Symptom
I Jan I Feb I Mar I Apr I May I Jun I Jul I Aug I Sep I O c t :  I N o v  I Dec I
Diagnostic criteria of severity of symptoms.
MILD - Minor symptoms and signs suffered to warrant treatment, but 
insufficient to greatly alter daily lifestyle.
MODERATE - More marked symptoms and signs sufficient to alter lifestyle, 
eg confined to home, time off work.
SEVERE - Marked symptoms and signs requiring frequent medical care, 
sufficient to alter normal lifestyle and activities.
If increased - Severe I I Moderate I I Mild I I
NOTE:
PC1AAJ
1 7 9 i
FORM III
A R I S E N  SKIN TEST REACTION AND ORDER FORM
EASE CO MPLETE EVERY SECTIO N)
Patient's Surname 
enamels)
i ' l l ! : ' ' ! ! ; ! ! ! :  Date or* Birth A g p
! ■ i t *i : 1 1 t ; ! j I ! • Name of Hosoital H p n t
A rtnrPh?;
IUK. w-r.*.vs
M firc K  R ef. N o . H n c n  R e f. N o .*• UC* CAhdULi ............
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APPENDIX IE
RESULTS OF IN IT IA L ALLERGY SCREENING
1. Distribution of skin test reactions to different allergens. Table 8.
2. Age of onset of symptoms. Table 9.
3. Results of preliminary screening. Table 10.
1 8 2
TABLE 8. DISTRIBUTION OF SKIN TEST REACTIONS TO DIFFERENT ALLERGENS.
++++++++ +++++++ ++++++ +++++ ++++ +++ ++ + Total
Grass 1 1 1 6 11 18 10 6 54Barley 9 14 9 3 35Wheat 1 9 5 4 19Maize 1 1Rye 1 1 2Flower 1 1 8 10Weed 1 1 2 10 14Tree 2 1 2 3 8Birch 1 1 2 4Ash 1 1Beech 1 1Hazel 1 1H.D. Mite 1 1 6 10 6 8 32House Dust 3 16 11 30Hay Dust 1 2 3Mould 1 1Aspergillus 1 1Cat 2 1 3 6Dog 2 2Horse 3 3Rabbit 1 1Budgies 1 1Sheep Wool 1 1 2Attemis 1 1 1 1 4Botrytis 1 1Otun 1 1Leather 1 1Candida 1 1Tusarium 1 1Uadosperium 1 1Fungi 1 4 5Cereals 3 - but with ill-defined degree of reaction \
Control positive, tests negative 3All tests negative 3
1 8 3
i
TABLE 9 . Age at onset of symptoms
PERENNIAL SEASONAL SEASONAL AND PERENNIAL
MALE FEMALE MALE FEMALE MALE FEMALE
Very young 1 16 weeks 12 years 13 years 15 years 16 years 1 1 17 years 18 years 19 years 1 2 110 years 311 years 1 312 years 1 113 years 1 414 years 2 215 years 316 years 2 1 117 years 119 years 120 years 121 years 123 years 126 years 128 years 129 years 135 years 146 years 148 years 1
11 with 10 with 5 withuncertain uncertain uncertainage of onset age of onset age of onset
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Asthma B - Hayfever C - Eczema H.D.H. - House Dist Mite Table showing skin test reaction
SENSITIVITY
verysensitive
ExtremelySensitive
Verysensitive
Extremelysensitive
Verysensitive mild 86
Verysensitive
Verysensitive
Mildsensitive
verysensitive
OTHERS
H.D. MiteH.D.Moulds
H.D. Mite +
Flower ++ H.D.M. ++ H.D. ++
H.D.M. ++ H.D. ++
Flower mix + Weed mix + H.D.M. ++++++ H.D. +++
S5OMH§
INHALENTS
COE!ssM«(0
TREES
Birch ++
Tree ++++ Birch ++++
Tree mix ++
Tree Mix ++
Tree Mix +
POLLEN
Grass ++++ Barley ++++
Grass ++
Grass +++ Barley +++ Wheat +
Grass +++
Grass
Grass +++++ Barley ++++
Grass + + + + +  Barley ++++ Weed + +  Maize + +
Grass + +  Barley +
Grass mix ++++Barley +++ Wheat +++
Grass mix ++++Barley ++ Wheat ++
3HswCMSEASONALAGE AT ONSET
9 yrs
35 yrs
14 yrs
10 yrs
14 yrs
13 yrs
15 yrs
5 yrs
3 yrs
13 yrs
coXoH
< co
< cq
CQ
n a
< CQ
< n
<
CQ
< CQ
CQ
XcoSEX
X
Cm
X
X
Cm
Cm
X
X
X
X
AGE
19 yrs
44 yrs
16 yrs
15 yrs
25 yrs
25 yrs
38 yrs
17 yrs
16 yrs
22 yrs
NAME
nco
(0cm
A.G.
CQCO
Q
F.C.
COH
Cm<
COX
DCM
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Asthma B - Hayfever C - Eczema H.D.H. - House Dist Mite Table showing skin test reaction
SENSITIVITY
I
Verysensitive
Verysensitive
Verysensitive
Verysensitive
Verysensitive
Verysensitive
Extremelysensitive
Verysensitive
Extremelysensitive
Verysensitive 85 mild 86
Verysensitive
OTHERS i
Weed + H.D.M. +++ H.D. ++
H.D.M. +++ H.D. ++
H.D.M. ++++ H.D. ++
H.D.M. +++ H.D. +
H.D.M.H.D.
H.D.M. +
ZoHEh%g
COEHZWZM
COwHzH«CO
, ............... 'TREES i
Birch ++
Tree ++++BirchMoulds
Tree mix ++
ZW■J►QOft
Grass ++++ Wheat +++
Grass +++ Barley ++
Grass ++++ Barley + + + +
Grass ++
Grass + + +  Barley + + +  Wheat +
Grass +++
Grass
Grass +++++ Barley ++++
3Mgw •ftSEASONALAGE AT ONSET
-----------------------1
6 yrs
13 yrs
48 yrs
16 yrs
9 yrs
35 yrs
14 yrs
10 yrs
14 yrs
13 yrs
SYMPTOMS
CQ
CQ
< n
Rhinitissneezing
Rhinitis
<
< CQ
CQ
« u
< CQ
< CQ
SEX
ft
ft
ft
ft
X
X
ft
X
X
ft
ft
AGE
17 yrs
19 yrs
50 yrs
22 yrs
10 yrs
19 yrs
44 yrs
16 yrs
15 yrs
25 yrs
25 yrs
NAME
J.L.
H.P.
L.B.
R. A.
<J
nCO
COEH
oCO
CQCO
Qft
uw
k
1
8
9
>ifl) H > 0) -He -p0) -H P m ■p e  X V w oi
■O 01 •O 01•O oi i-( c•rl 0)£  oi
>1 01 P C 0) V > 01 0) V > 01£  01£  01> 01
X +  +•H +E X +  +
co•H-P0a01 P
4->01
fl)■P
C•HX01
O'c•rlsJS01
+ -p
4) £  
O Qrl •Pn to
>  *0 •  •O fl) Q Qi—I fl) • •(m S B I SQ Qto to
+  +
+  +fl)•p
>1 +  oi fl) fl) fflrlTJ N Id P fl)-HM fl oi d u ta s £
•H£ oi 0)01 i—I «  P P id O CQ
01 0) -P01 h  id id + P fl) p + « JS U + tQ S
01 fl) 4J 01 H- rH Id
O CQ
0)0130to
1
to
o
to
E0)Nuw
I
<  Eh HW  CQ O £< O
P
fl)>0)
<  to
idJH•P01<
l
<
1 9 0
i
APPENDIX IV
IMMUNOASSAY REAGENTS ALLERGEN-SPECIFIC IMM UNOGLOBUL INS
1. Enzymeimmuno reagents For IgE assay.
2. Enzymeimmuno reagents for IgG4 assay.
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1. Enzyme Immunoassay Reagents for IgE
(1) Enzyme-Anti-Ige conjugate solution: The anti-IgE is purified from an 
antiserum raised in rabbits.
(2) Washing Solution: Washing solution additive (16 ml) and NaCl powder 
(9 g) are made up to 1 litre with redistilled water.
(3) Development Solution: This is reconstituted by adding a to b.
(a) Development reagent, O-nitrophenyl-B-galactoside (substrate) and 
glutathione (reducing agent). (Lyophilized)
(b) Development solution buffer, 13 ml.
(4) Stop Solution: Dissolve stop substance, (sodium carbonate powder, 4.2 g) 
in 100 ml redistilled water.
(5) Reference Discs (in buffer solution): Allergen discs impregnated with 
Timothy grass allergen.
(6) Reference sera (human serum).
Serum A is prepared from a standardized human serum pool w ith a high 
content of IgE specific the reference allergen (birch). Sera B, C and D  are 
standardized dilutions (1:5, 1:25, 1:50) of serum A prepared w ith a buffer 
solution containing bovine serum.
1 9 2
2. Enzyme Immunoassay Reagents for IgG4
(1) Enzyme-Anti-IgG (mouse monoclonal) conjugate.
(2) Development Solution: reconstitute by adding a to b.
(a) Development reagent, O-nitrophenyl-B-galactoside (substrate) and 
glutathione (reducing agent). (Lyophilized)
(b) Development solution buffer, 13 ml.
(3) Stop Solution. Stop substance, (sodium carbonate powder 4.2 g) made up 
to 100 ml with redistilled water.
(4) Washing Solution: Washing solution additive liquid 16 ml + washing 
solution concentrate liquid (50 ml) + 1 litre, redistilled water.
(5) Reference Reagents
Reference tubes coated with birch allergen.
(7) Reference Sera: Prepared from a standardized human serum pool with a 
high content of IgG4 antibodies specific for the reference allergen (birch).
(8) Preparation of Samples.The serum sample is diluted 1:50 w ith sample 
diluent.
1 9 3  -
APPENDIX V
Clinical Summary of Allergic and non-allergic women.
Clinical Details of women attending Langold Health Centre Ante-natal Clinic 
between September 1986 and December 1990.
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Table 21. Clinical Summary of Women Attending Lanqold Health CentreAnte-natal Clinic, September 1986 to December 1990.
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MISCARRIAGES BETWEEN OCTOBER 1986 - DECEMBER 1990. WON-ALLERGIC PATIENTS
MEDICAL HISTORY
otitis externa
tonsillitis otitis externa
no significant illnesses
no significant illnesses
otitis media I
no significant illnesses
anxiety state polyps
no significant illnesses
tonsillitis glandular fever
OBSTETRIC HISTORY
not known
2 normal deliveries
2 normal births 1 termination 1 twin pregnancy
1 normal delivery 1 miscarriage
not known
4 normal deliveries 1 miscarriage
1 miscarriage 1 termination 3 normal deliveries
1 miscarriage 1 normal birth
1 miscarriage Infertility Clinic normal birth 1989
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NORMAL BIRTHS BETWEEN OCTOBER 1986 - DECEMBER 1990. ALLERGIC PATIENTS. (Continued)
iI?}I\
| MEDICAL HISTORY
no significant illnesses
vertigo
no significant illnesses impetigo
no significant illnesses
mastoidectomy vaginal warts otitis media anxiety state
tonsillitis bronchitis vertigo anxiety state
tonsillitis |
Psychiatric referral for depression
no significant illness |
no significant illness
no significant illness
no significant illness |
no significant illness psoriasis
OBSTETRIC HISTORY
1
miscarriage 1986 termination 1986 normal delivery 1988 premature delivery 1987
treated with Clomiphene miscarriage normal delivery 1990
termination normal delivery
normal delivery
LSCS 1986 3 miscarriages miscarriages 1 normal delivery
1 miscarriage2 normalovarian cystectomy
normal
1 LSCS 3 normal
termination 1988
normal
normal
normal
normal
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